US20040014755A1 - Rho-kinase inhibitors - Google Patents
Rho-kinase inhibitors Download PDFInfo
- Publication number
- US20040014755A1 US20040014755A1 US10/339,393 US33939303A US2004014755A1 US 20040014755 A1 US20040014755 A1 US 20040014755A1 US 33939303 A US33939303 A US 33939303A US 2004014755 A1 US2004014755 A1 US 2004014755A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- halogen
- etoac
- compound according
- hplc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*(C1)C1c1c(C)c(C=NC)cc(NC(C(C(C=C2)=C)=C2N=C(C)Nc2cc(C(C)(C)C)n[n]2C)=I)c1 Chemical compound C*(C1)C1c1c(C)c(C=NC)cc(NC(C(C(C=C2)=C)=C2N=C(C)Nc2cc(C(C)(C)C)n[n]2C)=I)c1 0.000 description 22
- KQKGFBSRIQEEOB-UHFFFAOYSA-N ClC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound ClC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 KQKGFBSRIQEEOB-UHFFFAOYSA-N 0.000 description 4
- JEKASZPHONLRDZ-UHFFFAOYSA-N [Ar]C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound [Ar]C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 JEKASZPHONLRDZ-UHFFFAOYSA-N 0.000 description 4
- UMIIABSEBQEFPL-UHFFFAOYSA-N C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 Chemical compound C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 UMIIABSEBQEFPL-UHFFFAOYSA-N 0.000 description 3
- SSQKYRNYYPJIDN-UHFFFAOYSA-N FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 SSQKYRNYYPJIDN-UHFFFAOYSA-N 0.000 description 3
- ZURYIRRFPLTYLB-UHFFFAOYSA-N [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(OC)=C3)=NC3=C1C(C)=CO3)=C2 Chemical compound [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(OC)=C3)=NC3=C1C(C)=CO3)=C2 ZURYIRRFPLTYLB-UHFFFAOYSA-N 0.000 description 3
- UJTKZWNRUPTHSB-UHFFFAOYSA-N BrC1=CC=C(N2CCOCC2)C=C1 Chemical compound BrC1=CC=C(N2CCOCC2)C=C1 UJTKZWNRUPTHSB-UHFFFAOYSA-N 0.000 description 2
- MXIIWZUVANLOQS-UHFFFAOYSA-N C.CN1CCCCC1.CN1N=NC2=C1C=CC=C2 Chemical compound C.CN1CCCCC1.CN1N=NC2=C1C=CC=C2 MXIIWZUVANLOQS-UHFFFAOYSA-N 0.000 description 2
- KQTXKBCQYMSBRK-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2 KQTXKBCQYMSBRK-UHFFFAOYSA-N 0.000 description 2
- IDVYIGNCBLVAEV-UHFFFAOYSA-N C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 Chemical compound C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 IDVYIGNCBLVAEV-UHFFFAOYSA-N 0.000 description 2
- RCNLKUWHGZSAEY-UHFFFAOYSA-N C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 Chemical compound C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 RCNLKUWHGZSAEY-UHFFFAOYSA-N 0.000 description 2
- IPQWKUMBZBLJHG-UHFFFAOYSA-N C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 Chemical compound C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 IPQWKUMBZBLJHG-UHFFFAOYSA-N 0.000 description 2
- FVEVZFAIMYRAFY-UHFFFAOYSA-N C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 FVEVZFAIMYRAFY-UHFFFAOYSA-N 0.000 description 2
- VMVGFFVJOLJRMB-UHFFFAOYSA-N C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 VMVGFFVJOLJRMB-UHFFFAOYSA-N 0.000 description 2
- RWNUWKZDSIHFOE-UHFFFAOYSA-N C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1 Chemical compound C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1 RWNUWKZDSIHFOE-UHFFFAOYSA-N 0.000 description 2
- IHIQYDQAUMJZLK-UHFFFAOYSA-N C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 IHIQYDQAUMJZLK-UHFFFAOYSA-N 0.000 description 2
- WCOQLHINPQSOJI-UHFFFAOYSA-N C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 WCOQLHINPQSOJI-UHFFFAOYSA-N 0.000 description 2
- ZNZJGIVVJZDMOO-UHFFFAOYSA-N CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 ZNZJGIVVJZDMOO-UHFFFAOYSA-N 0.000 description 2
- BLZKSRBAQDZAIX-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)S1 Chemical compound CC1=CC2=C(C=CC=C2)S1 BLZKSRBAQDZAIX-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N CC1=CC=C(C(C)C)C=C1 Chemical compound CC1=CC=C(C(C)C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- ZYLPQYYLLRBVOK-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2)N=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2)N=C1 ZYLPQYYLLRBVOK-UHFFFAOYSA-N 0.000 description 2
- LONDBHTYIYKOCM-UHFFFAOYSA-N CC1=CC=CC(C2=CC=CN=C2)=C1 Chemical compound CC1=CC=CC(C2=CC=CN=C2)=C1 LONDBHTYIYKOCM-UHFFFAOYSA-N 0.000 description 2
- IYASLOPLXIQSIF-UHFFFAOYSA-N CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 Chemical compound CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 IYASLOPLXIQSIF-UHFFFAOYSA-N 0.000 description 2
- GFNVPUBIQQGKSL-UHFFFAOYSA-N CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 Chemical compound CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 GFNVPUBIQQGKSL-UHFFFAOYSA-N 0.000 description 2
- ZTERILKIUSLFNC-UHFFFAOYSA-N CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 ZTERILKIUSLFNC-UHFFFAOYSA-N 0.000 description 2
- HMVIELWIRQJXIP-UHFFFAOYSA-N CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1 Chemical compound CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1 HMVIELWIRQJXIP-UHFFFAOYSA-N 0.000 description 2
- SRNGZJVKXZDZOO-UHFFFAOYSA-N CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 SRNGZJVKXZDZOO-UHFFFAOYSA-N 0.000 description 2
- CHLICZRVGGXEOD-UHFFFAOYSA-N COC1=CC=C(C)C=C1 Chemical compound COC1=CC=C(C)C=C1 CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 2
- NFQGQMBFMIIIOR-UHFFFAOYSA-N COC1=CC=C(C)C=N1 Chemical compound COC1=CC=C(C)C=N1 NFQGQMBFMIIIOR-UHFFFAOYSA-N 0.000 description 2
- XJONVSUBOVWLRE-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1CO Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1CO XJONVSUBOVWLRE-UHFFFAOYSA-N 0.000 description 2
- ZKQNXPCLRCZANW-UHFFFAOYSA-N Cc1cc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc(C)c1 Chemical compound Cc1cc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc(C)c1 ZKQNXPCLRCZANW-UHFFFAOYSA-N 0.000 description 2
- BXVRFBZKYWYJMX-UHFFFAOYSA-N Cc1ccc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc1 Chemical compound Cc1ccc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc1 BXVRFBZKYWYJMX-UHFFFAOYSA-N 0.000 description 2
- GYQHQWLUSASIOK-UHFFFAOYSA-N FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 GYQHQWLUSASIOK-UHFFFAOYSA-N 0.000 description 2
- ABKVVJMMIKHYGF-UHFFFAOYSA-N O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 ABKVVJMMIKHYGF-UHFFFAOYSA-N 0.000 description 2
- WXMDFQBZMATQMY-UHFFFAOYSA-N OB(O)C1=CC2=C(C=CN=C2)S1 Chemical compound OB(O)C1=CC2=C(C=CN=C2)S1 WXMDFQBZMATQMY-UHFFFAOYSA-N 0.000 description 2
- WHDIUBHAKZDSJL-UHFFFAOYSA-N OB(O)C1=CC=C(N2CCOCC2)C=C1 Chemical compound OB(O)C1=CC=C(N2CCOCC2)C=C1 WHDIUBHAKZDSJL-UHFFFAOYSA-N 0.000 description 2
- MTGDUKHAVRDWDY-UHFFFAOYSA-N OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 Chemical compound OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 MTGDUKHAVRDWDY-UHFFFAOYSA-N 0.000 description 2
- FEWCHHMJNIOLJK-UHFFFAOYSA-N B.B.B.B.B.CC.CC.CC.CC.CC.CCCN.ClC1=NC([Ar])=NC=C1.NC(=O)CCNC(=O)[Ar].O=C(O)CCNC(=O)[Ar].O=P(Cl)(Cl)Cl.OC1=NC([Ar])=NC=C1 Chemical compound B.B.B.B.B.CC.CC.CC.CC.CC.CCCN.ClC1=NC([Ar])=NC=C1.NC(=O)CCNC(=O)[Ar].O=C(O)CCNC(=O)[Ar].O=P(Cl)(Cl)Cl.OC1=NC([Ar])=NC=C1 FEWCHHMJNIOLJK-UHFFFAOYSA-N 0.000 description 1
- FCDYQSLGMHZTMG-UHFFFAOYSA-N B.B.C.CC.CC.ClC1=NC([Ar])=NC=C1.N#CCCN=[N+]=[N-].O=P(Cl)(Cl)Cl Chemical compound B.B.C.CC.CC.ClC1=NC([Ar])=NC=C1.N#CCCN=[N+]=[N-].O=P(Cl)(Cl)Cl FCDYQSLGMHZTMG-UHFFFAOYSA-N 0.000 description 1
- LKPUVYBMIADJQZ-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 Chemical compound BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 LKPUVYBMIADJQZ-UHFFFAOYSA-N 0.000 description 1
- SFKKNJPOCYOGFL-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2.C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2.C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 SFKKNJPOCYOGFL-UHFFFAOYSA-N 0.000 description 1
- NQIBPFSFCNXUFV-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 NQIBPFSFCNXUFV-UHFFFAOYSA-N 0.000 description 1
- NIIUNMPDGHIKSC-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1.C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 Chemical compound BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1.C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 NIIUNMPDGHIKSC-UHFFFAOYSA-N 0.000 description 1
- WBCCOHBWOXCOOM-UHFFFAOYSA-N BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 WBCCOHBWOXCOOM-UHFFFAOYSA-N 0.000 description 1
- WMPUCCQKOROYET-UHFFFAOYSA-N BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 WMPUCCQKOROYET-UHFFFAOYSA-N 0.000 description 1
- KPNXDNUKSAMTMS-UHFFFAOYSA-N BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 KPNXDNUKSAMTMS-UHFFFAOYSA-N 0.000 description 1
- HNOBQASSISWFKX-UHFFFAOYSA-N BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1.CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 Chemical compound BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1.CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 HNOBQASSISWFKX-UHFFFAOYSA-N 0.000 description 1
- FIQNOUDKPNFVSO-UHFFFAOYSA-N C(CC1)CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C(CC1)CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 FIQNOUDKPNFVSO-UHFFFAOYSA-N 0.000 description 1
- MVSBUYCJZNDIFY-UHFFFAOYSA-N C(CC1)CCN1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C(CC1)CCN1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 MVSBUYCJZNDIFY-UHFFFAOYSA-N 0.000 description 1
- SDWUAUFCCAKIOB-UHFFFAOYSA-N C(c1ccccc1)N(CC1)CCC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C(c1ccccc1)N(CC1)CCC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 SDWUAUFCCAKIOB-UHFFFAOYSA-N 0.000 description 1
- GYRHNXAGXQMXGK-UHFFFAOYSA-N C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1 Chemical compound C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1 GYRHNXAGXQMXGK-UHFFFAOYSA-N 0.000 description 1
- TWMKGNRIJMWEJG-UHFFFAOYSA-N C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1.C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1.CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1.C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1.CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 TWMKGNRIJMWEJG-UHFFFAOYSA-N 0.000 description 1
- VWNQPZVBCYENDD-UHFFFAOYSA-N C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 Chemical compound C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 VWNQPZVBCYENDD-UHFFFAOYSA-N 0.000 description 1
- JGPZOJIGZHIJJN-UHFFFAOYSA-N C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2.C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl Chemical compound C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2.C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl JGPZOJIGZHIJJN-UHFFFAOYSA-N 0.000 description 1
- IUNMKJBAOCXXRH-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1 IUNMKJBAOCXXRH-UHFFFAOYSA-N 0.000 description 1
- FZZPWPPLAQRDTD-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1.C1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-].COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1.C1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-].COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 FZZPWPPLAQRDTD-UHFFFAOYSA-N 0.000 description 1
- QIHGDMHRBXJUQZ-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 QIHGDMHRBXJUQZ-UHFFFAOYSA-N 0.000 description 1
- CEIWBXPNGUTHAU-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2.C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2.C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 CEIWBXPNGUTHAU-UHFFFAOYSA-N 0.000 description 1
- HSWYIFZAAWZRNH-UHFFFAOYSA-N C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 HSWYIFZAAWZRNH-UHFFFAOYSA-N 0.000 description 1
- UOJUWUZAPBMFEY-UHFFFAOYSA-N C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2.C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 Chemical compound C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2.C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 UOJUWUZAPBMFEY-UHFFFAOYSA-N 0.000 description 1
- MKXFLBWELQORLT-UHFFFAOYSA-N C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2 Chemical compound C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2 MKXFLBWELQORLT-UHFFFAOYSA-N 0.000 description 1
- NPIXQBAALXSYJE-UHFFFAOYSA-N C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)C=O3)=C2 Chemical compound C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)C=O3)=C2 NPIXQBAALXSYJE-UHFFFAOYSA-N 0.000 description 1
- XWZGROYLNUBMRU-UHFFFAOYSA-N C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2 Chemical compound C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2 XWZGROYLNUBMRU-UHFFFAOYSA-N 0.000 description 1
- UJHUEIUHXMUYRO-UHFFFAOYSA-N C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 Chemical compound C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 UJHUEIUHXMUYRO-UHFFFAOYSA-N 0.000 description 1
- YFUPYFKWAAYFAX-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2 Chemical compound C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2 YFUPYFKWAAYFAX-UHFFFAOYSA-N 0.000 description 1
- QKWAHGAAYQJLLX-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1.CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1.CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QKWAHGAAYQJLLX-UHFFFAOYSA-N 0.000 description 1
- CQKLJHZSVBFTPO-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2 Chemical compound C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2 CQKLJHZSVBFTPO-UHFFFAOYSA-N 0.000 description 1
- DCPXQXJNVSBACU-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2.COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2.COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 DCPXQXJNVSBACU-UHFFFAOYSA-N 0.000 description 1
- NHUUQZVWYKDMPA-UHFFFAOYSA-N C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1.C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(CC)=C3)=NC3=C1C(C)=CO3)=C2 Chemical compound C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1.C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(CC)=C3)=NC3=C1C(C)=CO3)=C2 NHUUQZVWYKDMPA-UHFFFAOYSA-N 0.000 description 1
- MKYRMMMSZSVIGD-UHFFFAOYSA-N C1=CC2=C(C=CS2)C=N1 Chemical compound C1=CC2=C(C=CS2)C=N1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 1
- JCUXXRZOCBSXEA-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2 JCUXXRZOCBSXEA-UHFFFAOYSA-N 0.000 description 1
- SUTHFXHBOGENNX-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2.C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1.OC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.[H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1.[H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2.C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1.OC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.[H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1.[H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 SUTHFXHBOGENNX-UHFFFAOYSA-N 0.000 description 1
- JNUGTBANGQJXBV-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2 JNUGTBANGQJXBV-UHFFFAOYSA-N 0.000 description 1
- CBYVMSYVPVBCBU-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2 CBYVMSYVPVBCBU-UHFFFAOYSA-N 0.000 description 1
- FDMVOVJNPPCQHS-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2.C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1.C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1.FC1=CC2=C(C=C1)N/C=C\2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2.C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1.C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1.FC1=CC2=C(C=C1)N/C=C\2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 FDMVOVJNPPCQHS-UHFFFAOYSA-N 0.000 description 1
- ZIHQQENZZLYBIH-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2 ZIHQQENZZLYBIH-UHFFFAOYSA-N 0.000 description 1
- ZIWUELIXUCMXNG-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1.FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1.FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 ZIWUELIXUCMXNG-UHFFFAOYSA-N 0.000 description 1
- IMTDSNDLBFJQEW-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2 IMTDSNDLBFJQEW-UHFFFAOYSA-N 0.000 description 1
- VIRSHBOPSKNRAX-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2.CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2.CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 VIRSHBOPSKNRAX-UHFFFAOYSA-N 0.000 description 1
- LPFDOSZJNVVLNZ-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2 LPFDOSZJNVVLNZ-UHFFFAOYSA-N 0.000 description 1
- FKNQZWLLZHZXPI-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2 FKNQZWLLZHZXPI-UHFFFAOYSA-N 0.000 description 1
- DBHMDKCFPNGMLS-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2 DBHMDKCFPNGMLS-UHFFFAOYSA-N 0.000 description 1
- YLPOTUCWHWNTTQ-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2 YLPOTUCWHWNTTQ-UHFFFAOYSA-N 0.000 description 1
- FDVSDWZSEDVFRT-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2.FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2.FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 FDVSDWZSEDVFRT-UHFFFAOYSA-N 0.000 description 1
- XZVAHRAFAODYJZ-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2 XZVAHRAFAODYJZ-UHFFFAOYSA-N 0.000 description 1
- DKOXUQZDUKQDKE-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2.C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O.C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2.C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O.C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 DKOXUQZDUKQDKE-UHFFFAOYSA-N 0.000 description 1
- XIAABYZPOQNCMK-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2 XIAABYZPOQNCMK-UHFFFAOYSA-N 0.000 description 1
- NXAPLVDTZWKJSE-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2.C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2.C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 NXAPLVDTZWKJSE-UHFFFAOYSA-N 0.000 description 1
- QNOJDNFVZVNESL-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2 QNOJDNFVZVNESL-UHFFFAOYSA-N 0.000 description 1
- XSIVZELDUJDWSX-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2 XSIVZELDUJDWSX-UHFFFAOYSA-N 0.000 description 1
- QDCQTIYQCMXEGM-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2 QDCQTIYQCMXEGM-UHFFFAOYSA-N 0.000 description 1
- KERAZDRIXGRNGA-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2.C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2.C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 KERAZDRIXGRNGA-UHFFFAOYSA-N 0.000 description 1
- XOGDWKCZTPHMCC-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2 XOGDWKCZTPHMCC-UHFFFAOYSA-N 0.000 description 1
- IKEZOZKYBHSDAU-UHFFFAOYSA-N C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1 Chemical compound C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1 IKEZOZKYBHSDAU-UHFFFAOYSA-N 0.000 description 1
- QEKTXUOUPVHBEX-UHFFFAOYSA-N C1=CC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 Chemical compound C1=CC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 QEKTXUOUPVHBEX-UHFFFAOYSA-N 0.000 description 1
- QAGCBTSHBXBENJ-UHFFFAOYSA-N C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 Chemical compound C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 QAGCBTSHBXBENJ-UHFFFAOYSA-N 0.000 description 1
- KJSDEZJYBJFTQW-UHFFFAOYSA-N C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 KJSDEZJYBJFTQW-UHFFFAOYSA-N 0.000 description 1
- PJNKOTNMGSKMDF-UHFFFAOYSA-N C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C.CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C.CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 PJNKOTNMGSKMDF-UHFFFAOYSA-N 0.000 description 1
- NQMKDGVZZJHHSN-UHFFFAOYSA-N C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 NQMKDGVZZJHHSN-UHFFFAOYSA-N 0.000 description 1
- DARRGGQVCDUDHC-UHFFFAOYSA-N C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1.COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1.COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 DARRGGQVCDUDHC-UHFFFAOYSA-N 0.000 description 1
- ZOWIAAHMEMSWQS-UHFFFAOYSA-N C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 Chemical compound C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 ZOWIAAHMEMSWQS-UHFFFAOYSA-N 0.000 description 1
- UXTNNARPUJOMTG-UHFFFAOYSA-N C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+](O)C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+](O)C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 UXTNNARPUJOMTG-UHFFFAOYSA-N 0.000 description 1
- RULFELWNBPWZCH-UHFFFAOYSA-N C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1 Chemical compound C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1 RULFELWNBPWZCH-UHFFFAOYSA-N 0.000 description 1
- VBSKEAITLVMUQG-UHFFFAOYSA-N C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1 Chemical compound C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1 VBSKEAITLVMUQG-UHFFFAOYSA-N 0.000 description 1
- RBRQYFXELSVZBZ-UHFFFAOYSA-N C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 Chemical compound C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 RBRQYFXELSVZBZ-UHFFFAOYSA-N 0.000 description 1
- OZLCAJTZVYOASM-UHFFFAOYSA-N C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OZLCAJTZVYOASM-UHFFFAOYSA-N 0.000 description 1
- ZLLZPSBYGRUTGX-UHFFFAOYSA-N C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 ZLLZPSBYGRUTGX-UHFFFAOYSA-N 0.000 description 1
- QBJOVGQDIDGKQX-UHFFFAOYSA-N C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QBJOVGQDIDGKQX-UHFFFAOYSA-N 0.000 description 1
- QXUFVASYIVIXSV-UHFFFAOYSA-N C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QXUFVASYIVIXSV-UHFFFAOYSA-N 0.000 description 1
- BAIWWKYDHOXDSP-UHFFFAOYSA-N C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 BAIWWKYDHOXDSP-UHFFFAOYSA-N 0.000 description 1
- FAYMSHHQDAXTTQ-UHFFFAOYSA-N C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 FAYMSHHQDAXTTQ-UHFFFAOYSA-N 0.000 description 1
- NLXUAIQRVUSLDA-UHFFFAOYSA-N C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1 Chemical compound C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1 NLXUAIQRVUSLDA-UHFFFAOYSA-N 0.000 description 1
- UMXYIJYPXKXYMP-UHFFFAOYSA-N C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1.C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1.C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 UMXYIJYPXKXYMP-UHFFFAOYSA-N 0.000 description 1
- LMBZWBONVKZWHO-UHFFFAOYSA-N C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 LMBZWBONVKZWHO-UHFFFAOYSA-N 0.000 description 1
- ZOAVMURARHNLRU-UHFFFAOYSA-N C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 ZOAVMURARHNLRU-UHFFFAOYSA-N 0.000 description 1
- QRBMUNDOCCEZPZ-UHFFFAOYSA-N C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1 Chemical compound C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1 QRBMUNDOCCEZPZ-UHFFFAOYSA-N 0.000 description 1
- UZMHVOPBVHRESE-UHFFFAOYSA-N C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 UZMHVOPBVHRESE-UHFFFAOYSA-N 0.000 description 1
- AYVGHSUYXZNEHT-UHFFFAOYSA-N C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1 Chemical compound C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1 AYVGHSUYXZNEHT-UHFFFAOYSA-N 0.000 description 1
- JZNJTTNDMBGBQZ-UHFFFAOYSA-N C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1 Chemical compound C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1 JZNJTTNDMBGBQZ-UHFFFAOYSA-N 0.000 description 1
- DMVIOJXVRHRINI-UHFFFAOYSA-N C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1.CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 Chemical compound C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1.CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 DMVIOJXVRHRINI-UHFFFAOYSA-N 0.000 description 1
- WAZXEQMZULJSMP-UHFFFAOYSA-N C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 Chemical compound C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 WAZXEQMZULJSMP-UHFFFAOYSA-N 0.000 description 1
- KOQANVSOBLEXMO-UHFFFAOYSA-N C1=CN=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CN=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 KOQANVSOBLEXMO-UHFFFAOYSA-N 0.000 description 1
- PYDLMEYMWCOYPG-UHFFFAOYSA-N C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 PYDLMEYMWCOYPG-UHFFFAOYSA-N 0.000 description 1
- QIKQVAZJTHATHX-UHFFFAOYSA-N C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 QIKQVAZJTHATHX-UHFFFAOYSA-N 0.000 description 1
- IGHDTKAIZNKMKW-UHFFFAOYSA-N C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1 Chemical compound C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1 IGHDTKAIZNKMKW-UHFFFAOYSA-N 0.000 description 1
- QXQIULWVJALNPJ-UHFFFAOYSA-N C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1 Chemical compound C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1 QXQIULWVJALNPJ-UHFFFAOYSA-N 0.000 description 1
- JWIWNHHPWFYUJV-UHFFFAOYSA-N C1=CN=C2N=C(C3=CC4=C(C=CC=C4)S3)N=C(NC3=CC4=C(C=C3)NN=C4)C2=C1.CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 Chemical compound C1=CN=C2N=C(C3=CC4=C(C=CC=C4)S3)N=C(NC3=CC4=C(C=C3)NN=C4)C2=C1.CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 JWIWNHHPWFYUJV-UHFFFAOYSA-N 0.000 description 1
- QOYSEFFOZHXBNE-UHFFFAOYSA-N C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 QOYSEFFOZHXBNE-UHFFFAOYSA-N 0.000 description 1
- UDNWKFWVIGUBSU-UHFFFAOYSA-N C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 Chemical compound C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 UDNWKFWVIGUBSU-UHFFFAOYSA-N 0.000 description 1
- INILMQFHMXZLGJ-UHFFFAOYSA-N C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1 Chemical compound C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1 INILMQFHMXZLGJ-UHFFFAOYSA-N 0.000 description 1
- ZJPFELWHADKZLK-UHFFFAOYSA-N C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 ZJPFELWHADKZLK-UHFFFAOYSA-N 0.000 description 1
- XNZGSFFSQQJYQT-UHFFFAOYSA-N C1c2ccccc2CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C1c2ccccc2CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 XNZGSFFSQQJYQT-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N C=CC1=CC=C(C)C=C1 Chemical compound C=CC1=CC=C(C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- AGHNIKMPJPSAGP-UHFFFAOYSA-N C=CC1=CC=C(C)C=C1.CC1=CC(F)=CC(F)=C1.CC1=CC2=C(C=CC=C2)S1.CC1=CC=C(C(=O)N2CCOCC2)S1.CC1=CC=C(C)C=C1.CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1.CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=NC=C2)C=C1.CC1=CC=C(F)C(C2=CC=CC=C2)=C1.CC1=CC=C(F)C=C1.CC1=CC=C(N2CCNCC2)C=C1.CC1=CC=C(N2CCOCC2)C=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(F)=C1.CC1=CC=CC(OC(F)(F)F)=C1.CC1=CC=CC=C1.CCC1=CC=C(C)C=C1.CCOC1=CC(C)=CC=C1.COC1=CC(C)=CC=C1.COC1=CC=C(C)C=C1.COC1=CC=C(C)C=N1 Chemical compound C=CC1=CC=C(C)C=C1.CC1=CC(F)=CC(F)=C1.CC1=CC2=C(C=CC=C2)S1.CC1=CC=C(C(=O)N2CCOCC2)S1.CC1=CC=C(C)C=C1.CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1.CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=NC=C2)C=C1.CC1=CC=C(F)C(C2=CC=CC=C2)=C1.CC1=CC=C(F)C=C1.CC1=CC=C(N2CCNCC2)C=C1.CC1=CC=C(N2CCOCC2)C=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(F)=C1.CC1=CC=CC(OC(F)(F)F)=C1.CC1=CC=CC=C1.CCC1=CC=C(C)C=C1.CCOC1=CC(C)=CC=C1.COC1=CC(C)=CC=C1.COC1=CC=C(C)C=C1.COC1=CC=C(C)C=N1 AGHNIKMPJPSAGP-UHFFFAOYSA-N 0.000 description 1
- XXJLGOQYSDDNDK-UHFFFAOYSA-N C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O Chemical compound C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O XXJLGOQYSDDNDK-UHFFFAOYSA-N 0.000 description 1
- PYDDBTLSGBIRBR-UHFFFAOYSA-N CC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 Chemical compound CC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 PYDDBTLSGBIRBR-UHFFFAOYSA-N 0.000 description 1
- GNIQQKORSMFYPE-UHFFFAOYSA-N CC(=O)C1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound CC(=O)C1=CC=C(C2=CC=C(C)C=C2)C=C1 GNIQQKORSMFYPE-UHFFFAOYSA-N 0.000 description 1
- UBYHQVOLGNDPTL-UHFFFAOYSA-N CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 Chemical compound CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 UBYHQVOLGNDPTL-UHFFFAOYSA-N 0.000 description 1
- HSTAWSZUXOEPSG-UHFFFAOYSA-N CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 Chemical compound CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 HSTAWSZUXOEPSG-UHFFFAOYSA-N 0.000 description 1
- IEBHYKHHIAJQOK-UHFFFAOYSA-N CC(=O)NC1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound CC(=O)NC1=CC=C(C2=CC=C(C)C=C2)C=C1 IEBHYKHHIAJQOK-UHFFFAOYSA-N 0.000 description 1
- QLCNJFGDGYRFPQ-UHFFFAOYSA-N CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F Chemical compound CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F QLCNJFGDGYRFPQ-UHFFFAOYSA-N 0.000 description 1
- CRYWKOXFFOCIQK-UHFFFAOYSA-N CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F.CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C.FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F.CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C.FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 CRYWKOXFFOCIQK-UHFFFAOYSA-N 0.000 description 1
- ZZJRROKWGWYLBN-UHFFFAOYSA-N CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 Chemical compound CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 ZZJRROKWGWYLBN-UHFFFAOYSA-N 0.000 description 1
- YLVAYZGZKQSQEE-UHFFFAOYSA-N CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1.FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 Chemical compound CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1.FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 YLVAYZGZKQSQEE-UHFFFAOYSA-N 0.000 description 1
- GWURPOYXXCTONE-UHFFFAOYSA-N CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 GWURPOYXXCTONE-UHFFFAOYSA-N 0.000 description 1
- SHAMWVCDDZFIEL-UHFFFAOYSA-N CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 SHAMWVCDDZFIEL-UHFFFAOYSA-N 0.000 description 1
- NRKBPWBFTAVJCA-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1 NRKBPWBFTAVJCA-UHFFFAOYSA-N 0.000 description 1
- AQRCFAQUSISAMK-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 AQRCFAQUSISAMK-UHFFFAOYSA-N 0.000 description 1
- SMUDINOOORDNBZ-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1 SMUDINOOORDNBZ-UHFFFAOYSA-N 0.000 description 1
- WLWXNIPRLXZHMU-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl.CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl.CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 WLWXNIPRLXZHMU-UHFFFAOYSA-N 0.000 description 1
- NXOYDBQUTWVUSZ-UHFFFAOYSA-N CC.CC.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC=C3)=NC3=C1C=CO3)=C2 Chemical compound CC.CC.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC=C3)=NC3=C1C=CO3)=C2 NXOYDBQUTWVUSZ-UHFFFAOYSA-N 0.000 description 1
- BBCNOFQJHPPMRP-UHFFFAOYSA-N CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 BBCNOFQJHPPMRP-UHFFFAOYSA-N 0.000 description 1
- LHWACWFLWKKDPI-UHFFFAOYSA-N CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1 Chemical compound CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1 LHWACWFLWKKDPI-UHFFFAOYSA-N 0.000 description 1
- XZFNOQPCZWRESB-UHFFFAOYSA-N CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 XZFNOQPCZWRESB-UHFFFAOYSA-N 0.000 description 1
- VJYXZJGDFJJDGF-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC=C1 Chemical compound CC1=CC(C(F)(F)F)=CC=C1 VJYXZJGDFJJDGF-UHFFFAOYSA-N 0.000 description 1
- LNNBCDGBBKYJQW-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC=C1.CC1=CC(C2=CC=CS2)=CC=C1.CC1=CC(C2=CC=NC=C2)=CC=C1.CC1=CC(CO)=CC=C1.CC1=CC=C(C(C)(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(CO)C=C1.CC1=CC=C(N2CCCCC2)C=C1 Chemical compound CC1=CC(C(F)(F)F)=CC=C1.CC1=CC(C2=CC=CS2)=CC=C1.CC1=CC(C2=CC=NC=C2)=CC=C1.CC1=CC(CO)=CC=C1.CC1=CC=C(C(C)(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(CO)C=C1.CC1=CC=C(N2CCCCC2)C=C1 LNNBCDGBBKYJQW-UHFFFAOYSA-N 0.000 description 1
- AFOCNRSNOSLFHZ-UHFFFAOYSA-N CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 AFOCNRSNOSLFHZ-UHFFFAOYSA-N 0.000 description 1
- BOCLRFOJQFQHDM-UHFFFAOYSA-N CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 BOCLRFOJQFQHDM-UHFFFAOYSA-N 0.000 description 1
- NPDIDUXTRAITDE-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1 NPDIDUXTRAITDE-UHFFFAOYSA-N 0.000 description 1
- ZIEYQXYJGHFGFB-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1.CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1.CC1=CC=C(C2=CC=C(F)C=C2)C=C1.CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1.CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1.CC1=CC=C(C2=CC=CC=C2Cl)C=C1.CC1=CC=C(C2=CC=CC=C2F)C=C1.CC1=CC=C(C2=CC=CC=N2)C=C1.CC1=CC=C(C2=CN=CC=C2)C=C1.CC1=CC=C(Cl)C=C1.CC1=CC=CC(Cl)=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1F Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1.CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1.CC1=CC=C(C2=CC=C(F)C=C2)C=C1.CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1.CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1.CC1=CC=C(C2=CC=CC=C2Cl)C=C1.CC1=CC=C(C2=CC=CC=C2F)C=C1.CC1=CC=C(C2=CC=CC=N2)C=C1.CC1=CC=C(C2=CN=CC=C2)C=C1.CC1=CC=C(Cl)C=C1.CC1=CC=CC(Cl)=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1F ZIEYQXYJGHFGFB-UHFFFAOYSA-N 0.000 description 1
- SMKMXVCNNASZEB-UHFFFAOYSA-N CC1=CC(C2=CC=CS2)=CC=C1 Chemical compound CC1=CC(C2=CC=CS2)=CC=C1 SMKMXVCNNASZEB-UHFFFAOYSA-N 0.000 description 1
- IWRUAXOGIJVROI-UHFFFAOYSA-N CC1=CC(C2=CC=NC=C2)=CC=C1 Chemical compound CC1=CC(C2=CC=NC=C2)=CC=C1 IWRUAXOGIJVROI-UHFFFAOYSA-N 0.000 description 1
- JJCKHVUTVOPLBV-UHFFFAOYSA-N CC1=CC(CO)=CC=C1 Chemical compound CC1=CC(CO)=CC=C1 JJCKHVUTVOPLBV-UHFFFAOYSA-N 0.000 description 1
- YISYUYYETHYYMD-UHFFFAOYSA-N CC1=CC(F)=CC(F)=C1 Chemical compound CC1=CC(F)=CC(F)=C1 YISYUYYETHYYMD-UHFFFAOYSA-N 0.000 description 1
- AIKOPSMZPOGMSJ-UHFFFAOYSA-N CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1 Chemical compound CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1 AIKOPSMZPOGMSJ-UHFFFAOYSA-N 0.000 description 1
- AUTFAAZFCCPDHP-UHFFFAOYSA-N CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-] Chemical compound CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-] AUTFAAZFCCPDHP-UHFFFAOYSA-N 0.000 description 1
- PMMOKWBXWLBRPD-UHFFFAOYSA-N CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 PMMOKWBXWLBRPD-UHFFFAOYSA-N 0.000 description 1
- XHIPXDDGMZRSLF-UHFFFAOYSA-N CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 Chemical compound CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 XHIPXDDGMZRSLF-UHFFFAOYSA-N 0.000 description 1
- VFRHJBKHEQZRJM-UHFFFAOYSA-N CC1=CC=C(C(=O)N2CCOCC2)S1 Chemical compound CC1=CC=C(C(=O)N2CCOCC2)S1 VFRHJBKHEQZRJM-UHFFFAOYSA-N 0.000 description 1
- QCWXDVFBZVHKLV-UHFFFAOYSA-N CC1=CC=C(C(C)(C)C)C=C1 Chemical compound CC1=CC=C(C(C)(C)C)C=C1 QCWXDVFBZVHKLV-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N CC1=CC=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- SXVMLOJQVHAHHZ-UHFFFAOYSA-N CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1 Chemical compound CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1 SXVMLOJQVHAHHZ-UHFFFAOYSA-N 0.000 description 1
- QAOZLQJWOHCEOV-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(C)C([N+](=O)[O-])=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(C)C([N+](=O)[O-])=C2)C=C1 QAOZLQJWOHCEOV-UHFFFAOYSA-N 0.000 description 1
- XYOKCUNCQZYSPK-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1 XYOKCUNCQZYSPK-UHFFFAOYSA-N 0.000 description 1
- BBBFSPBYVBEIJU-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1 Chemical compound CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1 BBBFSPBYVBEIJU-UHFFFAOYSA-N 0.000 description 1
- JSBJQQZPQJIGFJ-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(F)C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(F)C=C2)C=C1 JSBJQQZPQJIGFJ-UHFFFAOYSA-N 0.000 description 1
- XAIDWOFGGNDTPE-UHFFFAOYSA-N CC1=CC=C(C2=CC=C([N+](=O)[O-])C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C([N+](=O)[O-])C=C2)C=C1 XAIDWOFGGNDTPE-UHFFFAOYSA-N 0.000 description 1
- WAEKCHUPDOGQJY-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1 WAEKCHUPDOGQJY-UHFFFAOYSA-N 0.000 description 1
- VXPLSDQTIWIHJH-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1 VXPLSDQTIWIHJH-UHFFFAOYSA-N 0.000 description 1
- JTZVTVSSLYYVAM-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC3=C2C=CC=C3)C=C1 Chemical compound CC1=CC=C(C2=CC=CC3=C2C=CC=C3)C=C1 JTZVTVSSLYYVAM-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2)C=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- LZQKARVGXYAKEN-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2Cl)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2Cl)C=C1 LZQKARVGXYAKEN-UHFFFAOYSA-N 0.000 description 1
- UZRWCXBSPNFXAK-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2F)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2F)C=C1 UZRWCXBSPNFXAK-UHFFFAOYSA-N 0.000 description 1
- KJNZQKYSNAQLEO-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=N2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=N2)C=C1 KJNZQKYSNAQLEO-UHFFFAOYSA-N 0.000 description 1
- DKFPQCUHILRPNN-UHFFFAOYSA-N CC1=CC=C(C2=CC=CS2)C=C1 Chemical compound CC1=CC=C(C2=CC=CS2)C=C1 DKFPQCUHILRPNN-UHFFFAOYSA-N 0.000 description 1
- MRAIVJPPOXSJNG-UHFFFAOYSA-N CC1=CC=C(C2=CC=NC=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=NC=C2)C=C1 MRAIVJPPOXSJNG-UHFFFAOYSA-N 0.000 description 1
- KUZNURGIXXKBEJ-UHFFFAOYSA-N CC1=CC=C(C2=CN=CC=C2)C=C1 Chemical compound CC1=CC=C(C2=CN=CC=C2)C=C1 KUZNURGIXXKBEJ-UHFFFAOYSA-N 0.000 description 1
- ZKYPCPPLWHALNY-UHFFFAOYSA-N CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl Chemical compound CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl ZKYPCPPLWHALNY-UHFFFAOYSA-N 0.000 description 1
- KMTDMTZBNYGUNX-UHFFFAOYSA-N CC1=CC=C(CO)C=C1 Chemical compound CC1=CC=C(CO)C=C1 KMTDMTZBNYGUNX-UHFFFAOYSA-N 0.000 description 1
- NPDACUSDTOMAMK-UHFFFAOYSA-N CC1=CC=C(Cl)C=C1 Chemical compound CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 1
- LOXSAAXJGAQNJU-UHFFFAOYSA-N CC1=CC=C(F)C(C2=CC=CC=C2)=C1 Chemical compound CC1=CC=C(F)C(C2=CC=CC=C2)=C1 LOXSAAXJGAQNJU-UHFFFAOYSA-N 0.000 description 1
- WRWPPGUCZBJXKX-UHFFFAOYSA-N CC1=CC=C(F)C=C1 Chemical compound CC1=CC=C(F)C=C1 WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 1
- SEKVDGJLBQJSTO-UHFFFAOYSA-N CC1=CC=C(N2CCCCC2)C=C1 Chemical compound CC1=CC=C(N2CCCCC2)C=C1 SEKVDGJLBQJSTO-UHFFFAOYSA-N 0.000 description 1
- ONEYFZXGNFNRJH-UHFFFAOYSA-N CC1=CC=C(N2CCNCC2)C=C1 Chemical compound CC1=CC=C(N2CCNCC2)C=C1 ONEYFZXGNFNRJH-UHFFFAOYSA-N 0.000 description 1
- OLAFVASCPJETBP-UHFFFAOYSA-N CC1=CC=C(N2CCOCC2)C=C1 Chemical compound CC1=CC=C(N2CCOCC2)C=C1 OLAFVASCPJETBP-UHFFFAOYSA-N 0.000 description 1
- MBEXEYJTRNLJBT-UHFFFAOYSA-N CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 MBEXEYJTRNLJBT-UHFFFAOYSA-N 0.000 description 1
- VHUDPMKBQFCVGJ-UHFFFAOYSA-N CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC.OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC.OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 VHUDPMKBQFCVGJ-UHFFFAOYSA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N CC1=CC=CC(C)=C1 Chemical compound CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- QDHTXXOHGMXWDR-UHFFFAOYSA-N CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 QDHTXXOHGMXWDR-UHFFFAOYSA-N 0.000 description 1
- OSOUNOBYRMOXQQ-UHFFFAOYSA-N CC1=CC=CC(Cl)=C1 Chemical compound CC1=CC=CC(Cl)=C1 OSOUNOBYRMOXQQ-UHFFFAOYSA-N 0.000 description 1
- BTQZKHUEUDPRST-UHFFFAOYSA-N CC1=CC=CC(F)=C1 Chemical compound CC1=CC=CC(F)=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 1
- WPBXTCORBJRRIM-UHFFFAOYSA-N CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 WPBXTCORBJRRIM-UHFFFAOYSA-N 0.000 description 1
- BVTQIWAXRJLDQW-UHFFFAOYSA-N CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C Chemical compound CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C BVTQIWAXRJLDQW-UHFFFAOYSA-N 0.000 description 1
- XTVBUDBKLBBUBT-UHFFFAOYSA-N CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 Chemical compound CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 XTVBUDBKLBBUBT-UHFFFAOYSA-N 0.000 description 1
- WRNXOOXIPSTAGJ-UHFFFAOYSA-N CC1=CC=CC(OC(F)(F)F)=C1 Chemical compound CC1=CC=CC(OC(F)(F)F)=C1 WRNXOOXIPSTAGJ-UHFFFAOYSA-N 0.000 description 1
- GGXKQILBNJUKSH-UHFFFAOYSA-N CC1=CC=CC2=C1C1=C(C=CC=C1)O2 Chemical compound CC1=CC=CC2=C1C1=C(C=CC=C1)O2 GGXKQILBNJUKSH-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N CC1=CC=CC=C1 Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- AEFCHOMXJJCVJW-UHFFFAOYSA-N CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 AEFCHOMXJJCVJW-UHFFFAOYSA-N 0.000 description 1
- GHGJRQUDLXQODE-UHFFFAOYSA-N CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1.CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1.CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 GHGJRQUDLXQODE-UHFFFAOYSA-N 0.000 description 1
- IPEZLDLJNUPTMI-UHFFFAOYSA-N CC1=COC(N)=C1C#N Chemical compound CC1=COC(N)=C1C#N IPEZLDLJNUPTMI-UHFFFAOYSA-N 0.000 description 1
- VBVWRIUMKXPHKC-UHFFFAOYSA-N CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1.COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1.COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 VBVWRIUMKXPHKC-UHFFFAOYSA-N 0.000 description 1
- MWYWRISDPFGRJI-UHFFFAOYSA-N CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 Chemical compound CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 MWYWRISDPFGRJI-UHFFFAOYSA-N 0.000 description 1
- HQMYDRGGBUKAKP-UHFFFAOYSA-N CC1=NNC2=C1C=C(N)C=C2 Chemical compound CC1=NNC2=C1C=C(N)C=C2 HQMYDRGGBUKAKP-UHFFFAOYSA-N 0.000 description 1
- LROBQAZPUIRMFF-UHFFFAOYSA-N CC1=NNC2=C1C=C(NC1=NC(Cl)=NC3=C1SC=C3)C=C2 Chemical compound CC1=NNC2=C1C=C(NC1=NC(Cl)=NC3=C1SC=C3)C=C2 LROBQAZPUIRMFF-UHFFFAOYSA-N 0.000 description 1
- ZGDNJFXKELMVLS-UHFFFAOYSA-N CC1=NNC2=C1C=C([N+](=O)[O-])C=C2 Chemical compound CC1=NNC2=C1C=C([N+](=O)[O-])C=C2 ZGDNJFXKELMVLS-UHFFFAOYSA-N 0.000 description 1
- LXBJRGMQQLEDOS-UHFFFAOYSA-N CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 LXBJRGMQQLEDOS-UHFFFAOYSA-N 0.000 description 1
- XPTAXIJFLRVNCG-UHFFFAOYSA-N CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1 Chemical compound CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1 XPTAXIJFLRVNCG-UHFFFAOYSA-N 0.000 description 1
- JRLPEMVDPFPYPJ-UHFFFAOYSA-N CCC1=CC=C(C)C=C1 Chemical compound CCC1=CC=C(C)C=C1 JRLPEMVDPFPYPJ-UHFFFAOYSA-N 0.000 description 1
- NHPDPRQIKQLPDJ-UHFFFAOYSA-N CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NHPDPRQIKQLPDJ-UHFFFAOYSA-N 0.000 description 1
- OCYLAWOZDBUXPT-UHFFFAOYSA-N CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C Chemical compound CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C OCYLAWOZDBUXPT-UHFFFAOYSA-N 0.000 description 1
- SNTATNAVBOJYNO-UHFFFAOYSA-N CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl Chemical compound CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl SNTATNAVBOJYNO-UHFFFAOYSA-N 0.000 description 1
- INHUETIDDHYTSJ-UHFFFAOYSA-N CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 INHUETIDDHYTSJ-UHFFFAOYSA-N 0.000 description 1
- UALKQROXOHJHFG-UHFFFAOYSA-N CCOC1=CC(C)=CC=C1 Chemical compound CCOC1=CC(C)=CC=C1 UALKQROXOHJHFG-UHFFFAOYSA-N 0.000 description 1
- MSESMLWUYPLOPX-UHFFFAOYSA-N CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 MSESMLWUYPLOPX-UHFFFAOYSA-N 0.000 description 1
- UEWVXVSAFDBVAF-UHFFFAOYSA-N CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 UEWVXVSAFDBVAF-UHFFFAOYSA-N 0.000 description 1
- RDNDORVEMOWCHU-UHFFFAOYSA-N CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 Chemical compound CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 RDNDORVEMOWCHU-UHFFFAOYSA-N 0.000 description 1
- WPFPDGUSKZUCPV-UHFFFAOYSA-N CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1.COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 Chemical compound CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1.COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 WPFPDGUSKZUCPV-UHFFFAOYSA-N 0.000 description 1
- PZTNKUBGTDUTFJ-UHFFFAOYSA-N CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 PZTNKUBGTDUTFJ-UHFFFAOYSA-N 0.000 description 1
- NDIONECNVSHGQJ-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 NDIONECNVSHGQJ-UHFFFAOYSA-N 0.000 description 1
- CEOJLFHUKHJSPL-UHFFFAOYSA-N CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 CEOJLFHUKHJSPL-UHFFFAOYSA-N 0.000 description 1
- LGDDCHFLNXAATA-UHFFFAOYSA-N CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 LGDDCHFLNXAATA-UHFFFAOYSA-N 0.000 description 1
- ZXUGSCWLYNXNTO-UHFFFAOYSA-N CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 ZXUGSCWLYNXNTO-UHFFFAOYSA-N 0.000 description 1
- LWJZDPHZRDBVQW-UHFFFAOYSA-N CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 LWJZDPHZRDBVQW-UHFFFAOYSA-N 0.000 description 1
- NQXDAWUZEFVGJN-UHFFFAOYSA-N COC(CCCC1=CSC=C1)OC Chemical compound COC(CCCC1=CSC=C1)OC NQXDAWUZEFVGJN-UHFFFAOYSA-N 0.000 description 1
- SZJMVVOLKZAPCJ-UHFFFAOYSA-N COC(CNCC1=CSC=C1)OC Chemical compound COC(CNCC1=CSC=C1)OC SZJMVVOLKZAPCJ-UHFFFAOYSA-N 0.000 description 1
- LDRKJRJZNPFAGB-UHFFFAOYSA-N COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 LDRKJRJZNPFAGB-UHFFFAOYSA-N 0.000 description 1
- GCILBUUASGQXAX-UHFFFAOYSA-N COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 GCILBUUASGQXAX-UHFFFAOYSA-N 0.000 description 1
- QTGFIKPKZATJSC-UHFFFAOYSA-N COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QTGFIKPKZATJSC-UHFFFAOYSA-N 0.000 description 1
- OSIGJGFTADMDOB-UHFFFAOYSA-N COC1=CC(C)=CC=C1 Chemical compound COC1=CC(C)=CC=C1 OSIGJGFTADMDOB-UHFFFAOYSA-N 0.000 description 1
- DESOLECJXURASU-UHFFFAOYSA-N COC1=CC(C2=NC3=C(C(C)=CO3)C(Cl)=N2)=CC=C1 Chemical compound COC1=CC(C2=NC3=C(C(C)=CO3)C(Cl)=N2)=CC=C1 DESOLECJXURASU-UHFFFAOYSA-N 0.000 description 1
- LHQRMHPMPXGWOC-UHFFFAOYSA-N COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 Chemical compound COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 LHQRMHPMPXGWOC-UHFFFAOYSA-N 0.000 description 1
- VPCRPOHXUAVIAS-UHFFFAOYSA-N COC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CC=CC=C2)=C1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1.ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound COC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CC=CC=C2)=C1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1.ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 VPCRPOHXUAVIAS-UHFFFAOYSA-N 0.000 description 1
- PFAKVKDJVNXTHH-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 PFAKVKDJVNXTHH-UHFFFAOYSA-N 0.000 description 1
- QYZQYRZOOMNZFU-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C(OC)=C1 Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C(OC)=C1 QYZQYRZOOMNZFU-UHFFFAOYSA-N 0.000 description 1
- ASKBXZKXIBPNRA-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1 ASKBXZKXIBPNRA-UHFFFAOYSA-N 0.000 description 1
- YCZRVSWTOURVPF-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1F Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1F YCZRVSWTOURVPF-UHFFFAOYSA-N 0.000 description 1
- OUTCYYYAEXRMSX-UHFFFAOYSA-N COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OUTCYYYAEXRMSX-UHFFFAOYSA-N 0.000 description 1
- UKJITNXLJTWKSO-UHFFFAOYSA-N COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 UKJITNXLJTWKSO-UHFFFAOYSA-N 0.000 description 1
- NHWARZRBHBWEMO-UHFFFAOYSA-N COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NHWARZRBHBWEMO-UHFFFAOYSA-N 0.000 description 1
- DULNUXJCAKPXPN-UHFFFAOYSA-N COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC Chemical compound COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC DULNUXJCAKPXPN-UHFFFAOYSA-N 0.000 description 1
- GJLJFKDTYCSJHJ-UHFFFAOYSA-N COC1=CC=C(OC)C(C2=CC=C(C)C=C2)=C1 Chemical compound COC1=CC=C(OC)C(C2=CC=C(C)C=C2)=C1 GJLJFKDTYCSJHJ-UHFFFAOYSA-N 0.000 description 1
- DFMSRYYRUVCEIA-UHFFFAOYSA-N COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 Chemical compound COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 DFMSRYYRUVCEIA-UHFFFAOYSA-N 0.000 description 1
- XTZJTWMCKGRTEH-UHFFFAOYSA-N COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 XTZJTWMCKGRTEH-UHFFFAOYSA-N 0.000 description 1
- MOGLXQSRGNEDDA-UHFFFAOYSA-N COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 MOGLXQSRGNEDDA-UHFFFAOYSA-N 0.000 description 1
- VNEDXWYHPUQYCK-UHFFFAOYSA-N COC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=CC=CC=C2)=C1 Chemical compound COC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=CC=CC=C2)=C1 VNEDXWYHPUQYCK-UHFFFAOYSA-N 0.000 description 1
- HYTDLRLCVTXBIB-UHFFFAOYSA-N COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 HYTDLRLCVTXBIB-UHFFFAOYSA-N 0.000 description 1
- GQBOWWOZQUDQTM-UHFFFAOYSA-N COc1cc(CCNc2nc(Nc3ccc4N[I]=Cc4c3)c3[s]ccc3n2)ccc1 Chemical compound COc1cc(CCNc2nc(Nc3ccc4N[I]=Cc4c3)c3[s]ccc3n2)ccc1 GQBOWWOZQUDQTM-UHFFFAOYSA-N 0.000 description 1
- DKIPYGFGYOTLFI-UHFFFAOYSA-N CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 Chemical compound CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 DKIPYGFGYOTLFI-UHFFFAOYSA-N 0.000 description 1
- HDNBODDGYMYCOS-UHFFFAOYSA-N CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1 Chemical compound CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1 HDNBODDGYMYCOS-UHFFFAOYSA-N 0.000 description 1
- GDXQXKYVDFJNSQ-UHFFFAOYSA-N C[n]1nc(C2CC2)cc1NC([I]=C1Nc2ccc3[nH]ncc3c2)=Nc2c1[s]cc2 Chemical compound C[n]1nc(C2CC2)cc1NC([I]=C1Nc2ccc3[nH]ncc3c2)=Nc2c1[s]cc2 GDXQXKYVDFJNSQ-UHFFFAOYSA-N 0.000 description 1
- PBHKWIHPJIOQFN-UHFFFAOYSA-N ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 PBHKWIHPJIOQFN-UHFFFAOYSA-N 0.000 description 1
- HCUBASBTMMZUPU-UHFFFAOYSA-N ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 HCUBASBTMMZUPU-UHFFFAOYSA-N 0.000 description 1
- WWEJIZIKCFFVTL-UHFFFAOYSA-N ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 Chemical compound ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 WWEJIZIKCFFVTL-UHFFFAOYSA-N 0.000 description 1
- JWPXLGSRPNFADF-UHFFFAOYSA-N ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 Chemical compound ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 JWPXLGSRPNFADF-UHFFFAOYSA-N 0.000 description 1
- XWQXNHLJOWNXDN-UHFFFAOYSA-N ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 XWQXNHLJOWNXDN-UHFFFAOYSA-N 0.000 description 1
- OPBUMIBJXVBSRN-UHFFFAOYSA-N ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OPBUMIBJXVBSRN-UHFFFAOYSA-N 0.000 description 1
- URFQABJIYGLVSI-UHFFFAOYSA-N ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 Chemical compound ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 URFQABJIYGLVSI-UHFFFAOYSA-N 0.000 description 1
- NFEVBKOAOVYROZ-UHFFFAOYSA-N ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 NFEVBKOAOVYROZ-UHFFFAOYSA-N 0.000 description 1
- VIILLCLNVSHWEG-UHFFFAOYSA-N ClC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 Chemical compound ClC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 VIILLCLNVSHWEG-UHFFFAOYSA-N 0.000 description 1
- KTUSZYRIKRSQDY-UHFFFAOYSA-N ClC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 Chemical compound ClC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 KTUSZYRIKRSQDY-UHFFFAOYSA-N 0.000 description 1
- AQECFYPZMBRCIA-UHFFFAOYSA-N ClC1=NC2=C(SC=C2)C(Cl)=N1 Chemical compound ClC1=NC2=C(SC=C2)C(Cl)=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 1
- JXBQZJFEMKROTK-UHFFFAOYSA-N ClC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound ClC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 JXBQZJFEMKROTK-UHFFFAOYSA-N 0.000 description 1
- XVEVLTZRLLPLLH-UHFFFAOYSA-N ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 XVEVLTZRLLPLLH-UHFFFAOYSA-N 0.000 description 1
- IKAPCBKKDJHLHH-UHFFFAOYSA-N ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 IKAPCBKKDJHLHH-UHFFFAOYSA-N 0.000 description 1
- GBZFNIMKWXDXTP-UHFFFAOYSA-N FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 GBZFNIMKWXDXTP-UHFFFAOYSA-N 0.000 description 1
- YPEBOWSSDQWOTD-UHFFFAOYSA-N FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 YPEBOWSSDQWOTD-UHFFFAOYSA-N 0.000 description 1
- DRYWXGZGAKQGAA-UHFFFAOYSA-N FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 DRYWXGZGAKQGAA-UHFFFAOYSA-N 0.000 description 1
- DEBUATKNJBXSKE-UHFFFAOYSA-N FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 DEBUATKNJBXSKE-UHFFFAOYSA-N 0.000 description 1
- MXSNODXSWLCMJB-UHFFFAOYSA-N FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 MXSNODXSWLCMJB-UHFFFAOYSA-N 0.000 description 1
- QGCYMEQUNBTFOP-UHFFFAOYSA-N FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 QGCYMEQUNBTFOP-UHFFFAOYSA-N 0.000 description 1
- NXZBGEWMDHHQGY-UHFFFAOYSA-N FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NXZBGEWMDHHQGY-UHFFFAOYSA-N 0.000 description 1
- ZSQFMCLZDUVPAM-UHFFFAOYSA-N FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 ZSQFMCLZDUVPAM-UHFFFAOYSA-N 0.000 description 1
- PIKBLFGLUAZKRQ-UHFFFAOYSA-N FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 PIKBLFGLUAZKRQ-UHFFFAOYSA-N 0.000 description 1
- JFADRESJYCVGDY-UHFFFAOYSA-N FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 JFADRESJYCVGDY-UHFFFAOYSA-N 0.000 description 1
- OSABSBVBDNJCIG-UHFFFAOYSA-N FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1 Chemical compound FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1 OSABSBVBDNJCIG-UHFFFAOYSA-N 0.000 description 1
- BEUHDYITCIXINS-UHFFFAOYSA-N FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1 Chemical compound FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1 BEUHDYITCIXINS-UHFFFAOYSA-N 0.000 description 1
- WRBDHRTTXPRHSH-UHFFFAOYSA-N FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 WRBDHRTTXPRHSH-UHFFFAOYSA-N 0.000 description 1
- MBSHRYLEVKPRLA-UHFFFAOYSA-N FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 MBSHRYLEVKPRLA-UHFFFAOYSA-N 0.000 description 1
- ARBLOBGESCQWQP-UHFFFAOYSA-N FC1=CC2=C(C=C1)NC=C2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound FC1=CC2=C(C=C1)NC=C2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 ARBLOBGESCQWQP-UHFFFAOYSA-N 0.000 description 1
- FMDJMRBYYXWLGR-UHFFFAOYSA-N FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 Chemical compound FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 FMDJMRBYYXWLGR-UHFFFAOYSA-N 0.000 description 1
- DAOWKVRWFJBYAQ-UHFFFAOYSA-N FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 DAOWKVRWFJBYAQ-UHFFFAOYSA-N 0.000 description 1
- FBCJAZLWFTWOEY-UHFFFAOYSA-N FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 FBCJAZLWFTWOEY-UHFFFAOYSA-N 0.000 description 1
- OUCMHFQMVMZWGQ-UHFFFAOYSA-N N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OUCMHFQMVMZWGQ-UHFFFAOYSA-N 0.000 description 1
- VRJPEHZUCRVBSK-UHFFFAOYSA-N NC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 Chemical compound NC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 VRJPEHZUCRVBSK-UHFFFAOYSA-N 0.000 description 1
- FHCNTCINOXNXLI-UHFFFAOYSA-N NC(=O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 Chemical compound NC(=O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 FHCNTCINOXNXLI-UHFFFAOYSA-N 0.000 description 1
- UURQINISCFSPEH-UHFFFAOYSA-N NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1 Chemical compound NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1 UURQINISCFSPEH-UHFFFAOYSA-N 0.000 description 1
- YCBXIRPRDFBICG-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 YCBXIRPRDFBICG-UHFFFAOYSA-N 0.000 description 1
- QPZWDCOQFBHSQT-UHFFFAOYSA-N Nc1cc(-c(nc2Nc3ccc4[nH]ncc4c3)nc3c2S=CC3)ccc1 Chemical compound Nc1cc(-c(nc2Nc3ccc4[nH]ncc4c3)nc3c2S=CC3)ccc1 QPZWDCOQFBHSQT-UHFFFAOYSA-N 0.000 description 1
- YKOKRQGCMCXUNG-UHFFFAOYSA-N O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1 Chemical compound O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1 YKOKRQGCMCXUNG-UHFFFAOYSA-N 0.000 description 1
- VFRMWDQEHAOULM-UHFFFAOYSA-N O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1)C1=CC=NC=C1 Chemical compound O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1)C1=CC=NC=C1 VFRMWDQEHAOULM-UHFFFAOYSA-N 0.000 description 1
- FPBBRCDRXSTXDL-UHFFFAOYSA-N O=C(O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 Chemical compound O=C(O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 FPBBRCDRXSTXDL-UHFFFAOYSA-N 0.000 description 1
- AYJXFQZSODZYKJ-UHFFFAOYSA-N O=C(O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 Chemical compound O=C(O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 AYJXFQZSODZYKJ-UHFFFAOYSA-N 0.000 description 1
- WPPLAJADAQYNPQ-UHFFFAOYSA-N O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 WPPLAJADAQYNPQ-UHFFFAOYSA-N 0.000 description 1
- DBVZIPOGYQOMSV-UHFFFAOYSA-N O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 Chemical compound O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 DBVZIPOGYQOMSV-UHFFFAOYSA-N 0.000 description 1
- NRXZSBZRFZUJMA-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NRXZSBZRFZUJMA-UHFFFAOYSA-N 0.000 description 1
- FDJPTGFKWCIKOP-UHFFFAOYSA-N O=[N+]([O-])C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound O=[N+]([O-])C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 FDJPTGFKWCIKOP-UHFFFAOYSA-N 0.000 description 1
- PVCSELWCLKDKAH-UHFFFAOYSA-N OC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 Chemical compound OC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 PVCSELWCLKDKAH-UHFFFAOYSA-N 0.000 description 1
- HNMBNHDWYBJZSZ-UHFFFAOYSA-N OC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 Chemical compound OC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 HNMBNHDWYBJZSZ-UHFFFAOYSA-N 0.000 description 1
- FKOXFLCICMLKKI-UHFFFAOYSA-N OC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound OC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 FKOXFLCICMLKKI-UHFFFAOYSA-N 0.000 description 1
- IOMJPWLUIGLVHV-UHFFFAOYSA-N OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 IOMJPWLUIGLVHV-UHFFFAOYSA-N 0.000 description 1
- ZMZKBMVSPVYPQG-UHFFFAOYSA-N OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 ZMZKBMVSPVYPQG-UHFFFAOYSA-N 0.000 description 1
- BPISCNPRTUYEGN-UHFFFAOYSA-N OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 BPISCNPRTUYEGN-UHFFFAOYSA-N 0.000 description 1
- FHQIDGWZDOKKDI-UHFFFAOYSA-N [H]N(CC1=CC=C(B(O)O)C=C1)C1=CC=CC=C1 Chemical compound [H]N(CC1=CC=C(B(O)O)C=C1)C1=CC=CC=C1 FHQIDGWZDOKKDI-UHFFFAOYSA-N 0.000 description 1
- NTVJHRKYOWMSDE-UHFFFAOYSA-N [H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1 Chemical compound [H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1 NTVJHRKYOWMSDE-UHFFFAOYSA-N 0.000 description 1
- LSJCLEMNBKGNIA-UHFFFAOYSA-N [H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 Chemical compound [H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 LSJCLEMNBKGNIA-UHFFFAOYSA-N 0.000 description 1
- RRZPPHRGDCRYJQ-UHFFFAOYSA-N [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)=CO3)=C2 Chemical compound [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)=CO3)=C2 RRZPPHRGDCRYJQ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N c1n[nH]c2ccccc12 Chemical compound c1n[nH]c2ccccc12 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
- the pathology of a number of human and animal diseases including hypertension, erectile dysfunction, coronary cerebral circulatory impairments, neurodegenerative disorders and cancer can be linked directly to changes in the actin cytoskeleton. These diseases pose a serious unmet medical need.
- the actin cytoskeleton is composed of a meshwork of actin filaments and actin-binding proteins found in all eukaryotic cells. In smooth muscle cells the assembly and disassembly of the actin cytoskeleton is the primary motor force responsible for smooth muscle contraction and relaxation.
- Rho Ras superfamily of GTPases. This subset currently consists of RhoA through E and RhoG (refereed to collectively as Rho), Rac 1 and 2, Cdc42Hs and G25K and TC10 isoforms (Mackay, et al. J Biol Chem 1998, 273, 20685).
- Rho RhoA
- RhoG RhoG
- Cdc42Hs Cdc42Hs
- G25K G25K
- TC10 TC10 isoforms
- Rho proteins controls the formation of actin stress fibers, thick bundles of actin filaments, and the clustering of integrins at focal adhesion complexes.
- Rac proteins control the formation of lamellopodia or membrane ruffles on the cell surface and Cdc42 controls filopodia formation.
- This family of proteins plays a critical part in the control of key cellular functions including cell movement, axonal guidance, cytokinesis, and changes in cell morphology, shape and polarity.
- Rho proteins can control different biological responses.
- Rho proteins are responsible for the calcium sensitization during smooth muscle contraction.
- the Rho GTPases are responsible for the cellular responses to agonist such as lysophosphatidic acid (LPA), thrombin and thromboxane A 2 (Fukata, et al. Trends Pharcol Sci 2001, 22, 32).
- LPA lysophosphatidic acid
- thrombin thrombin
- thromboxane A 2 thromboxane A 2
- Agonist response is coupled through heterotrimeric G proteins G alpha12 or G alpha13 (Goetzl, et al. Cancer Res 1999, 59, 4732; Buhl, et al. J Biol Chem 1995, 270, 24631) though other receptors maybe involved.
- Rho GTPases Upon activation Rho GTPases activate a number of downstream effectors including PIP5-kinase, Rhothekin, Rhophilin, PKN and Rho kinase isoforms ROCK-1/ROKbeta and ROCK-1/ROKalpha (Mackay and Hall J Biol Chem 1998, 273, 20685; Aspenstrom Curr Opin Cell Biol 1999, 11, 95; Amano, et al. Exp Cell Res 2000, 261, 44).
- Rho kinase was identified as a RhoA interacting protein isolated from bovine brain (Matsui, et al. Embo J 1996, 15, 2208). It is a member of the myotonic dystrophy family of protein kinase and contains a serine/threonine kinase domain at the amino terminus, a coiled-coil domain in the central region and a Rho interaction domain at the carboxy terminus (Amano, et al. Exp Cell Res 2000, 261, 44). Its kinase activity is enhanced upon binding to GTP-bound RhoA and when introduced into cells, it can reproduce many of the activities of activated RhoA.
- Rho kinase mediates calcium sensitization and smooth muscle contraction and inhibition of Rho kinase blocks 5-HT and phenylephrine agonist induced muscle contraction.
- Rho kinase When introduced into non-smooth muscle cells, Rho kinase induces stress fiber formation and is required for the cellular transformation mediated by RhoA (Sahai, et al. Curr Biol 1999 9 136).
- Rho kinase regulates a number of downstream proteins through phosphorylation, including myosin light chain (Somlyo, et al. J Physiol (Lond) 2000, 522 Pt 2, 177), the myosin light chain phosphatase binding subunit (Fukata, et al. J Cell Biol 1998, 141, 409) and LIM-kinase 2 ( Sumi, et al. J Bio Chem 2001, 276, 670).
- Rho kinase inhibitors for the treatment of human diseases.
- Several patents have appeared claiming (+)-trans-4-(1-aminoethyl)- 1 -(pyridin-4-ylaminocarbonyl)cyclohexane dihydrochloride monohydrate (WO-00078351, WO-00057913) and substituted isoquinolinesulfonyl (EP-00187371) compounds as Rho kinase inhibitors with activity in animal models.
- cardiovascular diseases such as hypertension (Uehata, et al.
- Rho kinase activity has benefits for controlling cerebral vasospasms and ischemia following subarachnoid hemorrhage ( Pharma Japan 199, 1470, 16).
- Rho Kinase inhibitors are useful as Rho Kinase inhibitors and thus have utilities in the treatment of hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases, thrombotic disorders, asthma, glaucoma and osteoporosis.
- the compounds of the invention are useful to treat erectile dysfunction, i.e., erectile dysfunction mediated by Rho-kinase.
- Erectile dysfunction can be defined as an inability to obtain or sustain an erection adequate for intercourse, WO 94/28902, U.S. Pat. No. 6,103,765 and U.S. Pat. No. 6,124,461.
- X is —(CH 2 ) x —, —O—(CH 2 ) n —, —S—(CH 2 ) n —, —NR 7 —CO—(CH 2 ) n —, —NR 7 —SO 2 —(CH 2 ) n —, —NR 7 —(CH 2 ) n —, or —(O)C—NR 7 —,
- each n is an integer which is independently 0, 1, 2 or 3,
- a and c are each independently —CR 5 ⁇ , —N ⁇ , or —NR 6 —, wherein one of a or c is —NR 6 —, and b is —CR 5 ⁇ or —N ⁇ ;
- A is H, halogen, —CO—OR 8 , —CO—R 8 , cyano, —OR 8 , —NR 8 R 9 , —CO—NR 8 R 9 , —NR 8 —CO—R 9 , —NR 8 —CO—OR 9 , —NR 8 —SO 2 —R 9 , —SR 8 , —SO 2 —R 8 , —SO 2 —NR 8 R 9 , NR 8 —CO—NHR 9 , or
- A is a 3-20 atom, preferably 5-15 atom, cyclic or polycyclic moiety, e.g., containing 1-4 rings, which optionally contain 1-3 N, O or S atoms per ring, and may optionally be aryl or heteroaryl.
- A may optionally be substituted up to 3 times by (i) C 1 -C 10 alkyl or C 2 -C 10 -alkenyl, each optionally substituted with halogen up to perhalo; (ii) C 3 -C 10 cycloalkyl; (iii) optionally substituted aryl; (iv) optionally substituted heteroaryl; (v) halogen; (vi) —CO—OR 8 ; (vii) —CO—R 8 ; (viii) cyano; (ix) —OR 8 , (x) —NR 8 R 13 ; (xi) nitro; (xii) —CO—NR 8 R 9 ; (xiii) —C 1 -C 10 -alkyl-NR 8 R 9 ; (xiv) —NR 8 —CO—R 12 ; (xv) —NR 8 —CO—OR 9 ; (xvi) —NR 8 —SO 2 —R 9 ;
- Ring B represents a fused 5- or 6-membered heterocyclic ring containing 1-2 O, N, and/or S atoms and 1-5 C atoms.
- R 1 , and R 6 -R 11 are each independently H and C 1-6 alkyl
- R 2 -R 5 are each independently (i) C 1-10 alkyl or C 2-10 -alkenyl each optionally substituted by amino, N-lower alkylamino, N,N-dilower alkylamino, N-lower alkanoylamino, hydroxy, cyano, —COOR 10 , —COR 14 , —OCOR 14 , —OR 10 , C 5-10 -heteroaryl, C 5-10 -heteroaryloxy, C 5-10 -heteroaryl-C 1-10 -alkoxy, or halogen up to perhalo; (ii) C 3 -C 10 cycloalkyl, in which 1-3 carbon atoms are optionally independently replaced by O, N or S; (iii) C 3-10 -cycloalkenyl; (iv) partially unsaturated C 5-10 -heterocyclyl; (v) aryl; (vi) heteroaryl; (vii)
- R 12 is H, C 1-6 -alkyl or C 5-10 -aryl
- R 13 is H, C 1-6 -alkyl or C 1-6 -alkoxy
- R 14 is lower alkyl or phenyl
- R 15 is lower alkyl, halogen, amino, N-lower alkyl amino, N,N-dilower alkylamino N-lower alkanoylamino, OH, CN, COOR 10 , —COR 14 or —OCOR 14 ;
- R 16 is hydrogen, C 1-6 -alkyl optionally substituted by halogen, up to perhalo, or C 5-10 -heteroaryl;
- —X-A is not CH 3 when B represents a thieno[3,2b]fused ring, and b and c are —CR 5 ⁇ , and a is NH;
- A is not phenyl when X is NH, B forms an imidazo fused ring, and -a-b-c- is —CR 5 ⁇ N—NR 6 — or —NR 6 ⁇ N—CR 5 —.
- suitable aryl or heteroaryl groups include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms.
- Each ring typically has 3-7 atoms.
- aryl or heteroaryl can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or 5-yl, 1,2,4-triazol-1-, -3- or B5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or
- Preferred moieties A include cyclohexyl; or C 5-12 -aryl or C 5-12 -heteroaryl each independently optionally substituted up to three times by (i) C 1 -C 10 -alkyl or C 2-10 -alkenyl each optionally substituted with halogen up to perhalo; (ii) C 3 -C 10 cycloalkyl; (iii) C 5-12 -aryl optionally substituted by 1-3 halogen atoms; (iv) C 5-12 -heteroaryl; (v) halogen; (vi) —CO—OR 8 ; (vii) —CO—R 8 ; (viii) cyano; (ix) —OR 8 ; (x) —NR 8 R 13 ; (xi) nitro; (xii) —CO—NR 8 R 9 ; (xiii) —C 1-10 -alkyl-NR 8 R 9 ; (xiv) ——
- moieties A include phenyl, pyridyl, pyrimidinyl, oxazolyl, furyl, thienyl, pyrrolyl, imidazolyl, isoxazolyl and pyrazinyl, each independently substituted up to three times by halogen, C 1-10 -alkyl, C 1-10 -alkoxyphenyl, naphthyl, —OR 10 ,
- each Z independently is halogen, hydroxy, hydroxy-C 1-10 -alkyl, —CN, —NO 2 , C 1-10 -alkoxycarboxyl, —NR 10 —CO—R 11 , or —NR 10 —CO—OR 11 , as well as OR 10 , y is 0-3, more preferably 1-3, and R 4 is as described above.
- Preferred moieties A additionally include
- R 15 is H; phenyl optionally substituted by C 1-10 -alkyl, C 1-10 -alkoxy, C 1-10 -alkylcarboxyl, or halogen; benzyl; pyrimidyl or pyridyl; and R 16 is H, phenyl, —COOR 10 ,
- Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic acid, phenylacetic acid, and mandelic acid.
- basic salts of inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic
- pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + , Na + or K + ), alkaline earth cations (e.g., Mg + , Ca + or Ba + ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, pyridine, N,N-dimethylaminopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- a number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art.
- the present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess Rho-kinase inhibitory activity.
- the invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- the invention moreover encompasses treating indications mediated by Rho-kinase, by administering a compound of Formula I, or a pharmaceutical composition containing a compound of Formula I.
- cardiovascular diseases such as hypertension, artherosclerosis, restenosis and cerebral ischemia, or vasospasm central nervous system disorders such as neuronal degeneration and spinal cord injury, erectile dysfunction, e.g., in patients who do not have satisfactory response to PDE-5 inhibitors, and cancer (e.g., tumor growth) mediated by Rho-kinase, by administering, e.g., to a host in need thereof, of an effective amount of a compound of Formula I.
- Cancers and tumors mediated by Rho-kinase include cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
- a number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art.
- the present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess Rho-kinase inhibitory activity.
- the invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- the invention moreover encompasses treating indications mediated by Rho-kinase, by administering a compound of Formula I, or a pharmaceutical composition containing a compound of Formula I.
- cardiovascular diseases such as hypertension, artherosclerosis, restenosis and cerebral ischemia, or vasospasm central nervous system disorders such as neuronal degeneration and spinal cord injury, erectile dysfunction, e.g., in patients who do not have satisfactory response to PDE-5 inhibitors, and cancer (e.g., tumor growth) mediated by Rho-kinase, by administering, e.g., to a host in need thereof, of an effective amount of a compound of Formula I.
- Cancers and tumors mediated by Rho-kinase include cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
- the compounds may be administered orally, topically, parenterally, by inhalation or spray, vaginally, rectally or sublingually in dosage unit formulations.
- administration by injection includes intravenous, intraarticular, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques.
- Dermal administration may include topical application or transdermal administration.
- One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions.
- Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., sodium EDTA
- suspending agent e.g., sodium EDTA
- preservatives e.g., sodium EDTA, sodium sulfate, sodium bicarbonate
- the compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; “Transdermal Controlled Systemic Medications”; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 Mar. 3, 1994).
- a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms.
- a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.
- Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane.
- Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
- Suitable penetration enhancing materials for transdermal delivery system include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C 8 -C 18 fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C 8 -C 18 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate,
- Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether.
- Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C 8 -C 18 fatty alcohols, saturated or unsaturated C 8 -C 18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated discarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
- Suitable binding materials for transdermal delivery systems include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers.
- Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.
- compositions of the invention may also be in the form of oil-in-water emulsions.
- the oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example, gum acacia or gum tragacanth, naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug.
- compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature or vaginal temperature and will therfore melt in the rectum or vagina to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- the present pharmaceutical compositions may take any form which is suitable for administration to the penis either via injection into the corpora cavernosa or transurethral administration, or topically applied to the urethral meatus.
- the pharmaceutical composition is suitably in the form of a saline solution.
- the pharmaceutical composition is in a form suitable for transurethral administration, and in this case the composition is typically in the form of a solution, an ointment, or a suppository.
- the pharmaceutical composition is administered 1 to 50 minutes, preferably 10 to 20 minutes, prior to the time of commencing sexual intercourse.
- the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily vaginal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily topical dosage regimen will preferably be from 0.01 to 200 mg administered between one to four times daily.
- the transdermal concentration will preferably be that required to maintain a daily dose is of from 0.1 to 200 mg/Kg.
- the daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.
- the optimal course of treatment i.e., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.
- the present compounds and compositions exhibit Rho-kinase inhibitory activity, and are thus useful to treat the indications listed above, e.g., indications mediated by Rho-kinase.
- indications mediated by Rho-kinase is meant diseases or conditions whose progression proceeds, at least in part, via the Rho pathway.
- Rho-kinase inhibitory activity e.g., ROCK-1 inhibition
- ROCK-1 inhibition can be evaluated as follows:
- the kinase domain of human ROCK-1, amino acids 27-530, is isolated as a glutathione S-transferase fusion protein from Sf9 insect cells.
- the protein is partially purified by glutathione Sepharose 4B (Pharmacia Biotech, Piscataway, N.J.) affinity purification.
- Reactions is carried out in 96-well plates in a total volume of 100 uL containing 50 mM N-[2-Hydoryethyl]piperaxine-N′-[2-ethanesulfonic acid] pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol, 6 ⁇ M ATP, 0.2 ⁇ Ci [ 33 P]ATP (NEN, Boston, Mass.), 1 ⁇ g myelin basic protein and 0.1 ⁇ g ROCK-1. Test compounds are dissolved in 100% dimethylsulfoxide, diluted to the appropriated concentration and added to the reaction. The final concentration of dimethylsulfoxide did not exceed 0.5%. The reaction is run for one hour at room temperature.
- the reaction is stopped with the addition of 7 mL of 1 N HCL, transferred to P30 membranes and the amount of [ 33 P]ATP, as counts per minute (c.p.m.) incorporated into the substrate, myelin basic protein, is read in a BetaPlate Reader (Packard Instrument Co., Meriden, Conn.). (All reagents were purchased from Sigma Chemical Co., St. Louis, Mo. unless stated otherwise.) Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
- Inhibitory activity can also be evaluated by measurement of stress fiber formation, performed essentially as described by Ridley, A. J., and A. Hall, Cell 70:389-399 (1992).
- Human fibrosarcoma HT1080 (CCL-121, American Type Culture Collection, Manassas, Va.) cells are plated on 22 ⁇ 22 mm #1 glass cover slips in six-well tissue culture plates (Costar) at 2.5 ⁇ 10 4 cells/well in Delbeco's modified Eagle's Medium (DMEM, Gibco) supplemented with 10% fetal calf serum. Cells are maintained in a humidified, 5% CO 2 atmosphere at 37° C.
- DMEM Delbeco's modified Eagle's Medium
- test compounds are dissolved in 100% dimethylsulfoxide, diluted to the appropriated concentration and added to the culture medium 60 minutes prior to the induction of stress fiber formation. The final concentration of dimethylsulfoxide did not exceed 0.25%.
- Stress fiber formation is induced by the addition of lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycerol-3-phosphate, Avanti Polar-Lipids, Alabaster, Ala.) to 10 ⁇ M final concentration in Delbeco's modified Eagle's Medium containing 0.1% fatty acid free bovine serum albumin for 15 minutes at 37° C.
- Cells are fixed with 4% paraformaldeyhde (Poly Scientific, Bay Shore, N.J.) in phosphate buffered saline (PBS) for 15 minutes. Cells are then washed 3 times in PBS and them permeabilized using a solution containing 40 mM piperazine-N-N′bis[2-ethanesulfonic acid], 50 mM N-[2-hydoryethyl]piperaxine-N′-[2-ethanesulfonic acid], 0.1% Triton X-100, 75 mM NaCl, mM MgCl 2 , 0.5 mM EGTA, pH 7.2 for 2 minutes at room temperature.
- PBS phosphate buffered saline
- the cells are washed 3 times for 5 minutes each in PBS and then actin stress fibers are stained using 10 units/mL rhodamine phalloidin (Molecular Probes, Eugene, Oreg.) in PBS for 60 minutes at room temperature.
- the cells are washed 3 times with PBS and the cover slips mounted on glass microscope slides.
- the percentage of stress fiber positive cells on each slide was determined visually using a Nikon Labphoto-2 microscope. At least 100 cells were counted per slide and experiments were done in duplicate. Percentage inhibition is measured by counting the number of stress fiber positive cells in the presence of the test compound when compared to the number of stress fiber positive cells in the absence of the test compound.
- the compounds of the invention can be made according to routine, conventional chemical methods, and/or as disclosed below, from starting materials which are either commercially available or produceable according to routine, conventional chemical methods. General methods for the preparation of the compounds are given below, and the preparation of representative compounds is specifically illustrated in the Examples.
- a mixture of compound 3 and a phenol, N-substituted amine, or N-substituted aniline (A-X—H. where X is O or NR 8 ) is heated to 140° C. for 2 hours. The mixture is cooled to room temperature and is treated with ether to form precipitate or purified by silica gel column chromatography. The precipitate is filtered, washed with ether several times, and is dried under high vacuum to provide product.
- a heterocyclic aminoester of Formula 6 is acylated with an aromatic acid chloride or anhydride, in a base such as pyridine.
- the amide ester product is converted to the amide acid of Formula 7 by hydrolysis, or if R′′ is methyl, by action of boron tribromide.
- Conversion of the acid to the amide of Formula 8 is accomplished by reaction of 7 with ammonia in the presence of catalysts such as DMAP and EDC. Cyclization to 9 may be carried out by heating the diamide 8 in the presence of a base such as sodium hydroxide.
- the chloro intermediate of Formula 10 is formed by treatment of 9 with a chlorinating agent such as phosphorous oxychloride.
- a cyanoheterocyclic amine of Formula 10 may be directly converted to compounds of Formula 4 by heating with a Vilsmeier reagent, prepared in situ by treatment of an aromatic N,N-dimethyl amide with a phosphorous oxychloride or oxalyl chloride and the like.
- Step 1 Preparation of 2,3-dichlorothieno[3,2-d]pyrimidine
- Step 2 Preparation of 4-(N-5-aminoindazole)-2-chloro-thieno[3,2-d]pyrimidine
- Step 3 Preparation of 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]-pyrimidin-4-amine
- N-BOC protected boronic acid used in step 3 BOC group was removed by TFA in CH 2 CL 2 at rt. Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 10% to 75%); (45 mg, 19% yield); LCMS m/z 528 (M+M)+).
- Step 2 Preparation of N-(1H-indazol-5-yl)-N-(5- ⁇ 4-[(2-pyridinylamino)methyl]-phenyl ⁇ -1-benzothien-7-yl)amine
- Step 1 Preparation of methyl 3-[(2-guinoxalinylcarbonyl)amino]-2-thiophenecarboxylate
- Step 2 Preparation of 3-[(2-guinoxalinylcarbonyl)amino]-2-thiophenecarboxylic acid
- Step 3 Preparation of N-[2-(aminocarbonyl)-3-thienyl]-2-quinoxalinecarboxamide
- Step 6 Preparation of N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)thieno[3,2-d]-pyrimidin-4-amine
- Step 2 Preparation of 4-chloro-2-(3-methoxyphenyl)-5-methylfuro[2,3-d]-pyrimidine
- the Vilsmeier Reagent was prepared by stirring of 3-methoxy-N,N-dimethylbenzamide (1.17 g, 7.9 mmol) and POCl 3 (3.0 g, 19.7 mmol) at 0° C. for 30 minutes. To this reagent was added 2-amino-4-methyl-3-furonitrile (1.0 g, 6.6 mmol) and dry dichloroethane (5.0 ml). The reaction mixture was heated to 40° C. and stirred at this temperature for 18 h. The mixture was then poured into ice water. After adjusting the pH of the solution to 9 via treatment with NaHCO 3 solution, the solution was extracted with dichloromethane. The organic layer was then dried and concentrated.
- Step 1 Preparation of 2-(3-aminophenyl)-N-(1H-indazol-5-yl)thieno[3,2-d]-pyrimidin-4-amine
- Step 2 Preparation of 2-(3-aminophenyl)-N-(1H-indazol-5-yl)thieno[3,2-d]-pyrimidin-4-amine
- Step 4 Preparation of 2-(1,1′-biphenyl-3-yl)-N-(3-methyl-1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine
- step 3 A procedure analogous for that of Example 1, step 3 was followed.
- a mixture of the step 3 product (0.4 g, 1.3 mmol), 3-phenylphenylboronic acid, (0.3 g, 1.5 mmol) and sodium bicarbonate (0.33 g, 3.9 mmol) in DME/H 2 O (3/1, 56 mL) was flushed with Ar for 1 h, and Pd(dppf)Cl 2 was added.
- the solution was heated to reflux for 48 h at 100° C.
- the crude product was purified by silica gel chromatography to afford a white solid (0.35 g, 65%).
- R 0.2 (EtOAc/hexane, 1/1).
- Step 1 Preparation of 2-[(1-benzothien-2-ylcarbonyl)amino]nicotinic acid
- Step 2 Preparation of 2-[(1-benzothien-2-ylcarbonyl)amino]nicotinamide
- Step 4 Preparation of 2-(1-benzothien-2-yl)-4-chloropyrido[2,3-d]pyrimidine
- Step 5 Preparation of N-[2-(1-benzothien-2-yl)pyrido[2,3-d]pyrimidin-4-yl]-N-(1H-indazol-5-yl)amine
- Step 2 Preparation of N-(2,2-dimethoxyethyl)-4-methyl-N-(3-thienylmethyl)-benzenesulfonamide
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/339,393 US20040014755A1 (en) | 2002-01-10 | 2003-01-10 | Rho-kinase inhibitors |
US11/733,045 US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US12/688,428 US20100216789A1 (en) | 2002-01-10 | 2010-01-15 | Rho-kinase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34662802P | 2002-01-10 | 2002-01-10 | |
US10/339,393 US20040014755A1 (en) | 2002-01-10 | 2003-01-10 | Rho-kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/733,045 Continuation US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040014755A1 true US20040014755A1 (en) | 2004-01-22 |
Family
ID=23360296
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/339,393 Abandoned US20040014755A1 (en) | 2002-01-10 | 2003-01-10 | Rho-kinase inhibitors |
US11/733,045 Expired - Fee Related US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US12/688,428 Abandoned US20100216789A1 (en) | 2002-01-10 | 2010-01-15 | Rho-kinase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/733,045 Expired - Fee Related US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US12/688,428 Abandoned US20100216789A1 (en) | 2002-01-10 | 2010-01-15 | Rho-kinase inhibitors |
Country Status (8)
Country | Link |
---|---|
US (3) | US20040014755A1 (de) |
EP (1) | EP1465900B1 (de) |
JP (1) | JP4505228B2 (de) |
AU (1) | AU2003202263A1 (de) |
CA (1) | CA2472619A1 (de) |
DE (1) | DE60320933D1 (de) |
ES (1) | ES2305435T3 (de) |
WO (1) | WO2003059913A1 (de) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142314A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
US20060142313A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanaphalan Nagarathnam | Rho-kinase inhibitors |
US20070259896A1 (en) * | 2004-12-23 | 2007-11-08 | Ruiping Liu | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US20080139595A1 (en) * | 2004-04-08 | 2008-06-12 | Bayer Healthcare Ag | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors |
US20080176871A1 (en) * | 2006-11-09 | 2008-07-24 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US20080249105A1 (en) * | 2003-12-09 | 2008-10-09 | Bayer Healthcare Ag | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases |
US20100204240A1 (en) * | 2007-09-21 | 2010-08-12 | Array Biopharma Inc. | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
WO2013137491A1 (ja) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
WO2013151186A1 (ja) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | エリスロポエチン産生細胞の誘導方法 |
WO2014160413A1 (en) | 2013-03-14 | 2014-10-02 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells |
WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (ja) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
WO2014200115A1 (ja) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬 |
WO2015020113A1 (ja) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
WO2015034012A1 (ja) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
EP3255142A1 (de) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Herstellung von kardiomyozyten |
WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
WO2018216743A1 (ja) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法 |
WO2019092939A1 (ja) | 2017-11-10 | 2019-05-16 | 株式会社リジェネシスサイエンス | 培養細胞の製造方法,脊髄損傷疾患の治療剤の製造方法 |
WO2019131940A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 多能性幹細胞凝集抑制剤 |
WO2019131941A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2019131942A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集促進剤 |
WO2019160148A1 (ja) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (ja) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞を含む細胞集団及びその製造方法 |
WO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
US11268069B2 (en) | 2014-03-04 | 2022-03-08 | Fate Therapeutics, Inc. | Reprogramming methods and cell culture platforms |
WO2022149616A1 (ja) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法 |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
WO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法 |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006040966A1 (ja) * | 2004-10-08 | 2006-04-20 | Astellas Pharma Inc. | 芳香環縮合ピリミジン誘導体 |
CA2602294C (en) | 2005-03-25 | 2015-02-24 | Tibotec Pharmaceuticals Ltd. | Heterobicylic inhibitors of hvc |
CA2605161A1 (en) | 2005-04-21 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
AR056347A1 (es) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas |
TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
WO2006137368A1 (ja) | 2005-06-21 | 2006-12-28 | Kowa Co., Ltd. | 緑内障の予防又は治療剤 |
US20070135499A1 (en) * | 2005-07-11 | 2007-06-14 | Aerie Pharmaceuticals, Inc. | Hydrazide compounds |
EP1910297B1 (de) * | 2005-07-11 | 2016-05-25 | Aerie Pharmaceuticals, Inc. | Isochinolinverbindungen |
JP4972552B2 (ja) | 2005-07-12 | 2012-07-11 | 興和株式会社 | 緑内障を予防又は治療する薬剤 |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
RU2441869C2 (ru) * | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
RU2008130111A (ru) | 2005-12-22 | 2010-01-27 | Алькон Рисерч, Лтд. (Us) | (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний |
EP1999135A2 (de) * | 2006-03-30 | 2008-12-10 | Takeda San Diego, Inc. | Kinase-inhibitoren |
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
PL2091918T3 (pl) * | 2006-12-08 | 2015-02-27 | Novartis Ag | Związki i kompozycje jako inhibitory kinazy białkowej |
KR101364277B1 (ko) | 2006-12-08 | 2014-02-21 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
WO2008133753A2 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
CN101827848B (zh) * | 2007-08-08 | 2012-11-07 | 葛兰素史密丝克莱恩有限责任公司 | 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物 |
KR20210070407A (ko) | 2007-08-29 | 2021-06-14 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
PL2610258T3 (pl) | 2007-10-19 | 2015-02-27 | Boehringer Ingelheim Int | Podstawione piperydyno-dihydrotienopirymidyny |
WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
WO2009050242A2 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine |
EP3109249A1 (de) | 2007-11-15 | 2016-12-28 | YM BioSciences Australia Pty Ltd | Stickstoffhaltige heterocyclische verbindungen |
US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
EP2265270A1 (de) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridin-kinase-inhibitoren |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2760562C (en) | 2009-05-01 | 2016-07-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
IN2012DN03312A (de) * | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
US20120309773A1 (en) * | 2009-12-23 | 2012-12-06 | Babu Yarlagadda S | Heterocyclic compounds as janus kinase inhibitors |
AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
US8759363B2 (en) | 2010-01-28 | 2014-06-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Quinazoline-based T cell proliferation inhibitors |
EP2624698A4 (de) * | 2010-10-08 | 2014-10-08 | Abbvie Inc | Furo-[3,2-d-]pyrimidin-verbindungen |
DK2638149T3 (da) | 2010-11-12 | 2019-08-12 | Univ Georgetown | Immortalisering af epitelceller og fremgangsmåder til anvendelse |
WO2012067664A1 (en) * | 2010-11-18 | 2012-05-24 | Glaxo Group Limited | Compounds |
EP2502924A1 (de) | 2011-03-24 | 2012-09-26 | Chemilia AB | Neue Pyrimidinderivate |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
AU2012284091B2 (en) | 2011-07-19 | 2015-11-12 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
CA3178138A1 (en) | 2011-12-06 | 2013-06-13 | Astellas Institute For Regenerative Medicine | Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof |
ES2917222T3 (es) | 2011-12-28 | 2022-07-07 | Kyoto Prefectural Public Univ Corp | Normalización del cultivo de células endoteliales de la córnea |
EP2711364A1 (de) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl oder benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs |
EP2711365A1 (de) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs |
WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
CN105263494A (zh) | 2013-03-15 | 2016-01-20 | 爱瑞制药公司 | 联合治疗 |
EP3029140A4 (de) | 2013-07-30 | 2017-06-28 | Kyoto Prefectural Public University Corporation | Hornhautendothel-zellmarker |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
EP3055301B1 (de) * | 2013-10-07 | 2019-11-20 | Kadmon Corporation, LLC | (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amin-derivate als rho kinase inhibitoren zur behandlung von autoimmun-erkrankungen |
JPWO2015064768A1 (ja) | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
TW201605867A (zh) * | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
CN105814195A (zh) | 2013-11-27 | 2016-07-27 | 京都府公立大学法人 | 层粘连蛋白应用于角膜内皮细胞培养 |
EP2905024A1 (de) | 2014-02-07 | 2015-08-12 | Institut Quimic De Sarriá Cets, Fundació Privada | Pyrido[2,3-d]pyrimidin-7(8H)-on-Derivate zur Behandlung von Flaviviridae Infectionen |
EP3119881B1 (de) | 2014-03-21 | 2023-03-01 | FUJIFILM Cellular Dynamics, Inc. | Herstellung von von dopaminergischen neuronen aus dem mittelhirn |
KR20170020527A (ko) | 2014-06-27 | 2017-02-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도 |
CN104530078B (zh) * | 2015-01-27 | 2017-03-22 | 山东大学 | 一种噻吩并[3,2‑d]嘧啶衍生物及其制备方法与应用 |
US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
DK3277799T3 (en) | 2015-04-03 | 2020-12-14 | Propagenix Inc | Ex vivo proliferation af epithelceller |
US10729691B2 (en) | 2015-06-26 | 2020-08-04 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
JP2018522867A (ja) * | 2015-06-26 | 2018-08-16 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 縮合二環式ピリミジン誘導体およびこれらの使用 |
EA201890153A1 (ru) * | 2015-06-26 | 2018-06-29 | КАДМОН КОРПОРЕЙШН, ЭлЭлСи | Ингибиторы поглощения глюкозы |
DK3347450T3 (da) | 2015-09-11 | 2021-05-31 | Propagenix Inc | Ex vivo-proliferation af epithelceller |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
CA3005751A1 (en) * | 2015-12-03 | 2017-06-08 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Thieno-pyrimidine derivatives and uses thereof |
EP3383877B1 (de) | 2015-12-03 | 2021-09-15 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Heterocyclische verbindungen und verwendungen davon |
CA3008171A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
PL3416658T3 (pl) | 2016-02-15 | 2023-09-04 | Kyoto Prefectural Public University Corporation | Funkcjonalna ludzka komórka śródbłonka rogówki i jej zastosowanie |
CN107652273B (zh) * | 2016-07-26 | 2020-05-01 | 沈阳药科大学 | 嘧啶类衍生物及其制备方法和应用 |
BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
JP7185631B2 (ja) | 2017-02-03 | 2022-12-07 | サータ セラピューティクス プロプライエタリー リミテッド | 抗線維化化合物 |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
CN111032662A (zh) | 2017-06-21 | 2020-04-17 | 尚医治疗有限责任公司 | 与ras超家族相互作用的用于治疗癌症、炎性疾病、ras蛋白病和纤维化疾病的化合物 |
US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
AU2018294054B2 (en) | 2017-06-30 | 2022-05-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
EA202090572A1 (ru) | 2017-09-01 | 2020-07-06 | Кадмон Корпорейшн, Ллк | ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ |
EP3841195A1 (de) | 2018-08-20 | 2021-06-30 | Propagenix Inc. | Epithelzellsphäroide |
EP3843845A4 (de) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | Hemmung von proteinkinasen zur behandlung von friedreich-ataxie |
CN113056556A (zh) | 2018-08-31 | 2021-06-29 | 学校法人同志社 | 用于对眼细胞进行保存或培养的组合物以及方法 |
WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN113015429A (zh) | 2018-10-02 | 2021-06-22 | 学校法人同志社 | 用于保存角膜内皮细胞的方法和容器 |
UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
CN113454076A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用于激活造血干细胞和祖细胞的芳香族化合物 |
CA3173725A1 (en) | 2020-02-27 | 2021-09-02 | Kyoto Prefectural Public University Corporation | Functional human corneal endothelial cells and application thereof |
CN115667504A (zh) | 2020-04-27 | 2023-01-31 | 诺华股份有限公司 | 用于眼细胞疗法的方法和组合物 |
CA3216719A1 (en) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
WO2023069949A1 (en) | 2021-10-18 | 2023-04-27 | Evia Life Sciences Inc. | Compositions and methods of use thereof for treating liver fibrosis |
WO2023067394A2 (en) | 2021-10-22 | 2023-04-27 | Evia Life Sciences Inc. | Methods for making extracellular vesicles, and compositions and methods of use thereof |
CN115925694A (zh) * | 2022-10-19 | 2023-04-07 | 成都海博为药业有限公司 | 一种pak4激酶抑制剂及其制备方法和用途 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
US5240940A (en) * | 1988-01-29 | 1993-08-31 | Dowelanco | Quinoline and cinnoline fungicide compositions |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5324839A (en) * | 1991-02-07 | 1994-06-28 | Roussel-Uclaf | Nitrogenous bicyclic derivatives substituted with benzyl |
US5817674A (en) * | 1991-02-07 | 1998-10-06 | Roussel Uclaf | Quinoline compounds |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5958944A (en) * | 1994-04-18 | 1999-09-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
US5977102A (en) * | 1996-03-06 | 1999-11-02 | Dr. Karl Thomae Gmbh | Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US6153617A (en) * | 1997-07-29 | 2000-11-28 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6218410B1 (en) * | 1996-08-12 | 2001-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicines comprising Rho kinase inhibitor |
US20010014679A1 (en) * | 1997-05-02 | 2001-08-16 | Tang Peng C. | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds |
US20010044442A1 (en) * | 1998-08-21 | 2001-11-22 | Parker Hughes Institute | Dimethoxy quinazolines for treating diabetes |
US6326373B1 (en) * | 1999-03-05 | 2001-12-04 | Parker Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245038A (en) * | 1987-11-06 | 1993-09-14 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
EP0831829B1 (de) * | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclische kondensierte pyrimidin-derivate |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
CA2214841A1 (en) | 1997-10-31 | 1999-04-30 | Lisa Mckerracher | Rho antagonists and their use to block inhibition of neurite outgrowth |
CZ20001709A3 (cs) * | 1997-11-11 | 2001-12-12 | Pfizer Products Inc. | Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
KR100415791B1 (ko) * | 1998-06-19 | 2004-01-24 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-디]피리미딘 화합물 |
CA2307285C (en) | 1998-08-17 | 2009-03-31 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of glaucoma |
SE515247C2 (sv) | 1998-09-04 | 2001-07-02 | Alfa Laval Agri Ab | Djurbås med fösningsorgan |
BR9916574A (pt) * | 1998-12-23 | 2001-10-02 | Bayer Ag | Policarbonatos com baixo ìndice de yellowness |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
DE19911510A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
WO2000057914A1 (fr) | 1999-03-25 | 2000-10-05 | Santen Pharmaceutical Co., Ltd. | Agents permettant d'abaisser la tension oculaire |
EP1163910B1 (de) | 1999-03-25 | 2007-09-26 | Mitsubishi Pharma Corporation | Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose |
EP1174150A4 (de) | 1999-04-22 | 2004-06-16 | Mitsubishi Pharma Corp | Präventiv-/heilmittel für angiostenose |
AU4144400A (en) | 1999-04-27 | 2000-11-10 | Mitsubishi Pharma Corporation | Preventives/remedies for liver diseases |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
WO2001028561A1 (en) | 1999-10-21 | 2001-04-26 | Merck & Co., Inc. | Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment |
WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
EP1326892A2 (de) | 2000-10-12 | 2003-07-16 | University of Rochester | Zusammensetzungen die die proliferation von krebszellen hemmen |
US20020132832A1 (en) | 2001-01-05 | 2002-09-19 | Mills Thomas M. | Treatment of erectile dysfunction |
HN2002000067A (es) * | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | Inhibidores de la rho - quinasa. |
WO2003062227A1 (en) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
-
2003
- 2003-01-10 WO PCT/US2003/000606 patent/WO2003059913A1/en active Application Filing
- 2003-01-10 JP JP2003560016A patent/JP4505228B2/ja not_active Expired - Fee Related
- 2003-01-10 ES ES03701278T patent/ES2305435T3/es not_active Expired - Lifetime
- 2003-01-10 DE DE60320933T patent/DE60320933D1/de not_active Expired - Lifetime
- 2003-01-10 EP EP03701278A patent/EP1465900B1/de not_active Expired - Fee Related
- 2003-01-10 CA CA002472619A patent/CA2472619A1/en not_active Abandoned
- 2003-01-10 US US10/339,393 patent/US20040014755A1/en not_active Abandoned
- 2003-01-10 AU AU2003202263A patent/AU2003202263A1/en not_active Abandoned
-
2007
- 2007-04-09 US US11/733,045 patent/US7648986B2/en not_active Expired - Fee Related
-
2010
- 2010-01-15 US US12/688,428 patent/US20100216789A1/en not_active Abandoned
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
US5240940A (en) * | 1988-01-29 | 1993-08-31 | Dowelanco | Quinoline and cinnoline fungicide compositions |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
US5324839A (en) * | 1991-02-07 | 1994-06-28 | Roussel-Uclaf | Nitrogenous bicyclic derivatives substituted with benzyl |
US5478938A (en) * | 1991-02-07 | 1995-12-26 | Roussel Uclaf | Nitrogenous bicyclic derivatives substituted with benzyl |
US5817674A (en) * | 1991-02-07 | 1998-10-06 | Roussel Uclaf | Quinoline compounds |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
US5958944A (en) * | 1994-04-18 | 1999-09-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
US5932470A (en) * | 1994-10-07 | 1999-08-03 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5977102A (en) * | 1996-03-06 | 1999-11-02 | Dr. Karl Thomae Gmbh | Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation |
US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
US6218410B1 (en) * | 1996-08-12 | 2001-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicines comprising Rho kinase inhibitor |
US20010014679A1 (en) * | 1997-05-02 | 2001-08-16 | Tang Peng C. | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds |
US6207148B1 (en) * | 1997-06-19 | 2001-03-27 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
US6153617A (en) * | 1997-07-29 | 2000-11-28 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
US20010044442A1 (en) * | 1998-08-21 | 2001-11-22 | Parker Hughes Institute | Dimethoxy quinazolines for treating diabetes |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6277989B1 (en) * | 1998-08-28 | 2001-08-21 | Scios, Inc. | Quinazoline derivatives as medicaments |
US6326373B1 (en) * | 1999-03-05 | 2001-12-04 | Parker Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US20020055514A1 (en) * | 1999-03-05 | 2002-05-09 | Parker Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142313A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanaphalan Nagarathnam | Rho-kinase inhibitors |
US20060142314A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
US20080249105A1 (en) * | 2003-12-09 | 2008-10-09 | Bayer Healthcare Ag | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases |
US20080139595A1 (en) * | 2004-04-08 | 2008-06-12 | Bayer Healthcare Ag | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors |
US8329716B2 (en) | 2004-04-08 | 2012-12-11 | Bayer Intellectual Property Gmbh | Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors |
US20100010017A1 (en) * | 2004-12-23 | 2010-01-14 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US20070259896A1 (en) * | 2004-12-23 | 2007-11-08 | Ruiping Liu | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US8211898B2 (en) | 2006-11-09 | 2012-07-03 | Ardea Biosciences, Inc. | Substituted thieno[3,2-d]pyrimidines as HIV inhibitors |
US8324223B2 (en) | 2006-11-09 | 2012-12-04 | Ardea Biosciences, Inc. | Substituted thieno [2,3-d] pyrimidines as HIV inhibitors |
EP2132211A2 (de) * | 2006-11-09 | 2009-12-16 | Ardea Biosciences, Inc. | 4-cyanphenylamino-substituierte bizyklische und heterozyklische verbindungen als hiv-hemmer |
US7595324B2 (en) | 2006-11-09 | 2009-09-29 | Ardea Biosciences, Inc. | Substituted thieno[3,2-D]pyrimidines as HIV inhibitors |
US20080176871A1 (en) * | 2006-11-09 | 2008-07-24 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US20090281124A1 (en) * | 2006-11-09 | 2009-11-12 | Ardea Biosciences | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
WO2008058285A3 (en) * | 2006-11-09 | 2009-04-09 | Ardea Biosciences Inc | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
EP2132211A4 (de) * | 2006-11-09 | 2011-12-07 | Ardea Biosciences Inc | 4-cyanphenylamino-substituierte bizyklische und heterozyklische verbindungen als hiv-hemmer |
US8853409B2 (en) | 2007-09-21 | 2014-10-07 | Array Biopharma Inc. | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
US8212045B2 (en) | 2007-09-21 | 2012-07-03 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
US20100204240A1 (en) * | 2007-09-21 | 2010-08-12 | Array Biopharma Inc. | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus |
US9079890B2 (en) | 2007-09-21 | 2015-07-14 | Array Biopharma Inc. | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives |
US9982235B2 (en) | 2009-04-22 | 2018-05-29 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US20100272695A1 (en) * | 2009-04-22 | 2010-10-28 | Alan Agulnick | Cell compositions derived from dedifferentiated reprogrammed cells |
US9988604B2 (en) | 2009-04-22 | 2018-06-05 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
EP3904505A1 (de) | 2009-04-22 | 2021-11-03 | Viacyte, Inc. | Zellzusammensetzungen aus entdifferenzierten neuprogrammierten zellen |
US11905530B2 (en) | 2009-04-22 | 2024-02-20 | Viacyte, Inc. | Cell encapsulation device comprising a pancreatic progenitor cell population |
EP4206319A1 (de) | 2009-10-16 | 2023-07-05 | The Scripps Research Institute | Induktion pluripotenter zellen |
EP3235901A1 (de) | 2009-10-16 | 2017-10-25 | The Scripps Research Institute | Induzierung pluripotenter zellen |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
EP4364797A2 (de) | 2009-10-19 | 2024-05-08 | FUJIFILM Cellular Dynamics, Inc. | Herstellung von kardiomyozyten |
EP3255142A1 (de) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Herstellung von kardiomyozyten |
US9447382B2 (en) | 2010-06-15 | 2016-09-20 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US10260048B2 (en) | 2010-06-15 | 2019-04-16 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
EP3382008A1 (de) | 2010-06-15 | 2018-10-03 | FUJIFILM Cellular Dynamics, Inc. | Erzeugung induzierter pluripotenter stammzellen aus kleinen volumina von peripherem blut |
WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US8691574B2 (en) | 2010-06-15 | 2014-04-08 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US10844356B2 (en) | 2010-12-22 | 2020-11-24 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
WO2013137491A1 (ja) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
WO2013151186A1 (ja) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | エリスロポエチン産生細胞の誘導方法 |
US9650610B2 (en) | 2013-03-14 | 2017-05-16 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
US10376545B2 (en) | 2013-03-14 | 2019-08-13 | Viacyte, Inc. | Methods for producing hormone secreting cells in a subject |
US11446335B2 (en) | 2013-03-14 | 2022-09-20 | Viacyte, Inc. | Cryopreserved endocrine cells that express chromogranin A |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
EP3521418A1 (de) | 2013-03-14 | 2019-08-07 | ViaCyte, Inc | Zellkultur |
WO2014160413A1 (en) | 2013-03-14 | 2014-10-02 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells |
WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (ja) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
WO2014200115A1 (ja) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬 |
WO2015020113A1 (ja) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
US9796962B2 (en) | 2013-08-07 | 2017-10-24 | Kyoto University | Method for generating pancreatic hormone-producing cells |
WO2015034012A1 (ja) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
US11268069B2 (en) | 2014-03-04 | 2022-03-08 | Fate Therapeutics, Inc. | Reprogramming methods and cell culture platforms |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
EP4328301A2 (de) | 2016-08-16 | 2024-02-28 | FUJIFILM Cellular Dynamics, Inc. | Verfahren zur differenzierung pluripotenter zellen |
EP4001403A1 (de) | 2016-08-16 | 2022-05-25 | FUJIFILM Cellular Dynamics, Inc. | Verfahren zur differenzierung pluripotenter zellen |
WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
WO2018216743A1 (ja) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法 |
WO2019092939A1 (ja) | 2017-11-10 | 2019-05-16 | 株式会社リジェネシスサイエンス | 培養細胞の製造方法,脊髄損傷疾患の治療剤の製造方法 |
WO2019131941A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2019131940A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 多能性幹細胞凝集抑制剤 |
WO2019131942A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集促進剤 |
WO2019160148A1 (ja) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (ja) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞を含む細胞集団及びその製造方法 |
WO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
WO2022149616A1 (ja) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法 |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
WO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法 |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Also Published As
Publication number | Publication date |
---|---|
JP4505228B2 (ja) | 2010-07-21 |
JP2005523251A (ja) | 2005-08-04 |
EP1465900B1 (de) | 2008-05-14 |
ES2305435T3 (es) | 2008-11-01 |
US7648986B2 (en) | 2010-01-19 |
US20100216789A1 (en) | 2010-08-26 |
WO2003059913A1 (en) | 2003-07-24 |
US20070238741A1 (en) | 2007-10-11 |
EP1465900A1 (de) | 2004-10-13 |
AU2003202263A1 (en) | 2003-07-30 |
CA2472619A1 (en) | 2003-07-24 |
DE60320933D1 (de) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1465900B1 (de) | Rho-kinase inhibitoren | |
CA2441501C (en) | Rho-kinase inhibitors | |
EP1370553B1 (de) | Rho-kinase inhibitoren | |
CA2409743C (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
US7592352B2 (en) | Substituted thieno and furo-pyridines | |
EP1720864B1 (de) | Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken | |
TWI413522B (zh) | 苯并二氮呯化合物及藥學組成物 | |
MX2007000631A (es) | Tienopirimidinas utiles como inhibidores de aurora cinasa. | |
KR20020038800A (ko) | 화학적 화합물 | |
US20040138249A1 (en) | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | |
US20100324041A1 (en) | Pyrrolopyridines as kinase inhibitors | |
US20140221370A1 (en) | Pyrrolopyridines as kinase inhibitors | |
EP2694518A1 (de) | Thieno[2, 3]-d pyrimidinderivate und ihre verwendung zur behandlung von arrhythmien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER CORPORATION, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGARATHNAM, DHANAPALAN;KHIRE, UDAY;ASGARI, DAVOUD;AND OTHERS;REEL/FRAME:014012/0153;SIGNING DATES FROM 20030402 TO 20030407 |
|
AS | Assignment |
Owner name: BAYER PHARMACEUTICALS CORPORATION, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:014125/0545 Effective date: 20030603 |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:015505/0665 Effective date: 20040614 |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:016201/0060 Effective date: 20050628 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:023027/0804 Effective date: 20071219 Owner name: BAYER HEALTHCARE LLC,NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:023027/0804 Effective date: 20071219 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 |